Heterocyclic derivatives with benzyl substitution in medium or macrocyclic rings and their use as orexin-2 receptor agonists
By designing heterocyclic derivatives with benzyl substitution in the medium or large rings as orexin-2 receptor agonists, the problem of poor properties of existing compounds was solved, and effective activation of orexin-2 receptors was achieved, significantly improving the treatment effect of related disorders.
Patent Information
- Application Number
- CN202611336852.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-09-03
- Filing Date
- 2021-09-03
- Publication Date
- 2026-11-17
AI Technical Summary
Existing orexin receptor agonists have poor physicochemical, pharmacological, and pharmaceutical properties when treating narcolepsy and other disorders associated with orexin deficiency and excessive sleepiness, and cannot effectively restore lost orexin signaling.
A class of heterocyclic derivatives with benzyl substitution in medium or macrocyclic rings were developed as potent agonists of orexin-2 receptors. When administered orally, intranasally, transmucosally, or transdermally, they can effectively activate orexin-2 receptors and regulate arousal.
These compounds possess improved physicochemical, pharmacological, and pharmaceutical properties, significantly increase wakefulness time, and reduce cataplexy-like events. They are applicable to a variety of orexin-related disorders, including narcolepsy, Parkinson's disease, and Alzheimer's disease, offering more effective therapeutic potential.
Smart Images

Figure CN123106673A_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application No. 202180074185.9, filed on September 3, 2021, entitled "Medium- or Macrocyclic Benzyl-substituted Heterocyclic Derivatives Thereof and Their Use as Orexin-2 Receptor Agonists" (the corresponding PCT application was filed on September 3, 2021, and has the application number PCT / US2021 / 049003).
[0002] Related applications This application claims priority to U.S. Provisional Application No. 63 / 074,220, filed September 3, 2020, the entire contents of which are incorporated herein by reference.
[0003] background This disclosure relates to small-molecule, potent agonists of the orexin-2 receptor (OX2R) designed for the treatment of narcolepsy and other disorders associated with orexin deficiency and / or excessive sleepiness. Narcolepsy affects approximately 1 in 2,000 people worldwide. Onset can occur during adolescence and last a lifetime, negatively impacting quality of life. Narcolepsy type 1 (NT1) is caused by the loss of neurons in the brain that produce orexin neuropeptides. There is no known cure, and currently approved treatments are symptomatic. Therefore, developing pharmaceutical agents to restore lost orexin signaling is crucial for treating the underlying cause of NT1.
[0004] In type 1 narcolepsy (NT1), the sole group of neurons producing orexin A and B (also known as hypothalamic-peptides-1 and 2) is disrupted by an immune mechanism that causes dysfunction of the arousal boundary. Mouse models of NT1 recreate the loss of orexin neurons and the two main symptoms observed in NT1 patients: excessive daytime sleepiness and cataplexy. Common symptoms of both type 1 and type 2 narcolepsy can include excessive daytime sleepiness, nighttime sleep disturbances and inappropriately timed rapid eye movement (REM) sleep, as well as sleep paralysis and hallucinations. Cataplexy is a sudden, reversible loss of muscle tone (atonicity during REM sleep) invading the waking state in response to emotional stimuli and is a specific symptom of NT1.
[0005] The two main symptoms of type 1 narcolepsy, excessive daytime sleepiness and cataplexy, can be reduced by reactivating orexin neurotransmission at OX2R in a mouse model. In mice, focal restoration of OX2R signaling via gene therapy in the dorsal pontine raphe nucleus and the hypothalamic tuberculomatous nucleus, respectively, in regions otherwise lacking orexin receptors, has reversed cataplexy-like events and sleep / wake splits. Intraventricular (ICV) administration of orexin A (OXA) has been shown to increase wakefulness and reduce cataplexy-like behavior in orexin-neuronal resection mice. In the NT1 mouse model, intraperitoneal or ICV administration of the selective OX2R agonist YNT-185 moderately increased wakefulness in wild-type (WT) and orexin ligand-deficient mice and reduced the REM sleep onset phase and cataplexy-like events. Subcutaneous administration of the selective OX2R agonist TAK-925 moderately increased wakefulness in WT mice but not in OX2R-knockout mice. Brain-penetrating and stable OX2R agonists would offer improvements to current treatment for NT1 patients. These OX2R agonists are bioavailable after alternative routes of administration (including, but not limited to, oral, intranasal, transmucosal, and transdermal) and bind with high affinity to effectively stimulate neurons regulating arousal. Indeed, preliminary clinical studies reported on TAK-925 have shown a trend toward significantly increased alertness and reduced cataplexy in NT1 individuals. Activation of OX1R is associated with mood regulation and reward behavior and may also contribute to arousal.
[0006] Orexin receptor agonists can also be used for other indications characterized by some degree of orexin neurodegeneration and excessive daytime sleepiness, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, multiple sclerosis, and traumatic brain injury. Because OX2R stimulation promotes wakefulness in orexin-intact animals, orexin receptor agonists can treat excessive daytime sleepiness in patients with normal orexin levels, including type 2 narcolepsy, idiopathic hypersomnia, or sleep apnea. Similarly, orexin receptor agonists can provide wakefulness-promoting benefits in recurrent hypersomnia (such as Clayton-Ray syndrome) or inappropriate sleep timing (i.e., circadian rhythm sleep disorders) such as delayed or advanced sleep phase disorders, shift work disorders, and jet lag. Abnormal daytime sleepiness, REM sleep onset, and cataplexy-like symptoms in rare genetic disorders (e.g., ADCA-DN, Kohl's syndrome, Möbius syndrome, Norrie disease, Niemann-Pick disease type C, and Prad-Willi syndrome) can be relieved with orexin receptor agonists. Other indications for which orexin receptor agonists are considered beneficial include attention deficit hyperactivity disorder, age-related cognitive impairment, metabolic syndrome and obesity, osteoporosis, heart failure, coma, and anesthesia recovery.
[0007] This disclosure stems from the need to provide other compounds with improved therapeutic potential for modulating orexin receptor activity (including activation of orexin-2 receptors) in the brain. In particular, compounds with improved physicochemical, pharmacological, and pharmaceutical properties compared to existing compounds are desired.
[0008] Overview In some respects, this disclosure provides compounds of formula (I'): (I'); Or its pharmaceutically acceptable salt, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl-or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; n is an integer in the range of 0 to 3; R a and R b Each of the following is independently H, halogen, -CN, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, wherein the -O(C1-C6 alkyl), -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally influenced by one or more R S Replace; or R a and R b Together with the atoms they are attached to, they form a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group, wherein the C3-C7 cyclic hydrocarbon group or the 3- to 7-membered heterocyclic hydrocarbon group is optionally surrounded by one or more R S replace; Each R S It is independently a halogen, -CN, -OH, -O (C1-C6 alkyl), -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C1-C6 haloalkyl; Z is either -O- or -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -OH, -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -SH, -S (C1-C6 alkyl), -S (C6-C 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 -NH (3- to 7-membered heterocyclic hydrocarbon group), wherein -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -S (C1-C6 alkyl), -S (C6-C6 alkyl)2, -NH (C1-C6 alkyl)2, -NH ... 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace; Each R 1S Independently, it is an oxo, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -S(C1-C6 alkyl), -SO2(C1-C6 alkyl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C7 cycloalkyl, or 3- to 7-membered heterocyclic alkyl group; Ar1 is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A1 replace; Each R A1 Independently, it is Ar2, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T either does not exist or is Ar2; Each Ar2 is independently C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 Replace; and Each R A2 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0009] In some respects, this disclosure provides compounds that are obtainable or obtained by methods for preparing compounds as described herein (e.g., methods comprising one or more steps described in Schemes 1-5).
[0010] In some aspects, this disclosure provides a pharmaceutical composition comprising a compound of this disclosure or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
[0011] In some respects, this disclosure provides intermediates as described herein that are suitable for use in methods for preparing compounds as described herein (e.g., the intermediates are selected from those described in Examples 1-37).
[0012] In some respects, this disclosure provides a method for modulating orexin-2 receptor activity (e.g., in vitro or in vivo), the method comprising contacting cells with an effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof.
[0013] In some respects, this disclosure provides a method for treating or preventing a disease or disorder disclosed herein in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0014] In some respects, this disclosure provides a method for treating a disease or disorder disclosed herein in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0015] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for modulating orexin-2 receptor activity (e.g., in vitro or in vivo).
[0016] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment or prevention of the diseases or disorders disclosed herein.
[0017] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment of diseases or disorders disclosed herein.
[0018] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for modulating orexin-2 receptor activity (e.g., in vitro or in vivo).
[0019] In some respects, this disclosure provides for the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of the diseases or disorders disclosed herein.
[0020] In some respects, this disclosure provides for the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of the diseases or disorders disclosed herein.
[0021] In some respects, this disclosure provides a method for preparing the compounds of this disclosure.
[0022] In some aspects, this disclosure provides a method for preparing a compound, the method comprising one or more steps described herein.
[0023] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. In this specification, singular forms also include plural forms unless the context clearly indicates otherwise. Although similar or equivalent methods and materials to those described herein may be used in the practice or experimentation of this disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference. References cited herein are not recognized as prior art to the claimed invention. In case of conflict, this specification (including definitions) shall prevail. Furthermore, the materials, methods, and examples described are merely exemplary and are not intended to be limiting. In case of conflict between the chemical structures and names of the compounds disclosed herein, the chemical structure shall prevail.
[0024] Other features and advantages of this disclosure will become apparent from the following detailed description and claims.
[0025] Detailed description This disclosure relates to macrocyclic ([1,1'-biphenyl]-3-ylmethyl)-substituted heterocyclic derivatives, prodrugs, and pharmaceutically acceptable salts thereof, which can modulate orexin-2 receptor activity and are therefore used in methods of treating humans or animals. This disclosure also relates to methods of preparing these compounds, pharmaceutical compositions comprising them, and their use in treating disorders involving orexin-2 receptors, such as narcolepsy, neurodegenerative disorders, symptoms of rare genetic disorders, mental health disorders, metabolic syndrome, osteoporosis, heart failure, coma, or recovery from anesthesia.
[0026] definition Unless otherwise stated, the following terms used in this specification and claims shall have the meanings set forth below.
[0027] Not wishing to be limited by this statement, it should be understood that while various options for the variables are described herein, this disclosure is intended to cover operable implementations with combinations of options. This disclosure can be interpreted as excluding inoperable implementations resulting from certain combinations of options. For example, while various options for variables X, L, and Y are described herein, this disclosure can be interpreted as excluding structures of inoperable compounds resulting from certain combinations of variables X, L, and Y (e.g., when each of X, L, and Y is -O-).
[0028] As used herein, the terms "alkyl," "C1, C2, C3, C4, C5, or C6 alkyl," or "C1-C6 alkyl" are intended to include C1, C2, C3, C4, C5, or C6 straight-chain (linear) saturated aliphatic hydrocarbon groups and C3, C4, C5, or C6 branched saturated aliphatic hydrocarbon groups. For example, C1-C6 alkyl is intended to include C1, C2, C3, C4, C5, and C6 alkyl groups. Examples of alkyl groups include portions having 1 to 6 carbon atoms, such as, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, or n-hexyl. In some embodiments, the straight-chain or branched alkyl group has six or fewer carbon atoms (e.g., C1-C6 for straight-chain and C3-C6 for branched-chain), and in another embodiment, the straight-chain or branched alkyl group has four or fewer carbon atoms.
[0029] As used herein, the term "optionally substituted alkyl" means an unsubstituted alkyl or an alkyl with a specified substituent that replaces one or more hydrogen atoms on one or more carbons of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbamoyloxy, arylcarbamoyloxy, alkoxycarbamoyloxy, aryloxycarbamoyloxy, carboxylic acid ester, alkyl carbonyl, aryl carbonyl, alkoxy carbonyl, amino carbonyl, alkylamino carbonyl, dialkylamino carbonyl, alkylthiocarbonyl, alkoxy, phosphate ester, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and urea), amidoyl, imino, mercapto, alkylthio, arylthio, thiocarbamate, sulfate, alkylsulfinyl, sulfonato, aminosulfonyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclic, alkylaryl or aromatic or heteroaromatic moiety.
[0030] As used herein, the term "alkenyl" includes unsaturated aliphatic groups that are similar in length and possible substitutions to the aforementioned alkyl groups but contain at least one double bond. For example, the term "alkenyl" includes straight-chain alkenyl groups (e.g., vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl) and branched alkenyl groups. In some embodiments, straight-chain or branched alkenyl groups have six or fewer carbon atoms in their backbone (e.g., C2-C6 for straight chains and C3-C6 for branched chains). The term "C2-C6" includes alkenyl groups containing 2-6 carbon atoms. The term "C3-C6" includes alkenyl groups containing 3-6 carbon atoms.
[0031] As used herein, the term "optionally substituted alkenyl" refers to an unsubstituted alkenyl or an alkenyl with a specified substituent that replaces one or more hydrogen atoms on one or more carbon atoms of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbamoyloxy, arylcarbamoyloxy, alkoxycarbamoyloxy, aryloxycarbamoyloxy, carboxylic acid ester, alkyl carbonyl, aryl carbonyl, alkoxy carbonyl, amino carbonyl, alkylamino carbonyl, dialkylamino carbonyl, alkylthiocarbonyl, alkoxy, phosphate ester, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and urea), amido, imino, mercapto, alkylthio, arylthio, thiocarbamate, sulfate, alkylsulfinyl, sulfonato, aminosulfonyl, sulfonamide, nitro, trifluoromethyl, cyano, heterocyclic, alkylaryl or aromatic or heteroaromatic moiety.
[0032] As used herein, the term "alkynyl" includes unsaturated aliphatic groups that are similar in length and possible substitutions to the alkyl groups described above, but contain at least one triple bond. For example, "alkynyl" includes straight-chain alkynyl groups (e.g., ethynyl, propynyl, butynyl, penynyl, hexynyl, hepynyl, octyynyl, nonynyl, decanynyl) and branched-chain alkynyl groups. In some embodiments, the straight-chain or branched alkynyl group has six or fewer carbon atoms in its main chain (e.g., C2-C6 for straight chains and C3-C6 for branched chains). The term "C2-C6" includes alkynyl groups containing 2-6 carbon atoms. The term "C3-C6" includes alkynyl groups containing 3-6 carbon atoms. The terms "C2-C6 alkenyl linker" or "C2-C6 alkenyl linker" as used herein are intended to include C2, C3, C4, C5, or C6 chain (straight or branched) divalent unsaturated aliphatic hydrocarbon groups. For example, C2-C6 sub-olefinic linkers are intended to include C2, C3, C4, C5 and C6 sub-olefinic linkers.
[0033] As used herein, the term "optionally substituted alkynyl" refers to an unsubstituted alkynyl or an alkynyl with a specified substituent that replaces one or more hydrogen atoms on one or more carbon atoms of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbamoyloxy, arylcarbamoyloxy, alkoxycarbamoyloxy, aryloxycarbamoyloxy, carboxylic acid ester, alkyl carbonyl, aryl carbonyl, alkoxy carbonyl, amino carbonyl, alkylamino carbonyl, dialkylamino carbonyl, alkylthiocarbonyl, alkoxy, phosphate ester, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and urea), amidoyl, imino, mercapto, alkylthio, arylthio, thiocarbamate, sulfate, alkylsulfinyl, sulfonato, aminosulfonyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclic, alkylaryl or aromatic or heteroaromatic moiety.
[0034] Other optionally substituted portions (such as optionally substituted cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups) include unsubstituted portions and portions having one or more specified substituents. For example, substituted heterocycloalkyl groups include those substituted with one or more alkyl groups, such as 2,2,6,6-tetramethyl-piperidinyl and 2,2,6,6-tetramethyl-1,2,3,6-tetrahydropyridinyl.
[0035] As used in this article, the term "cycloalkyl group" refers to a group having 3-30 carbon atoms (e.g., C3-C4). 12 C3-C 10 Cyclic hydrocarbons (or C3-C8) are monocyclic or polycyclic (e.g., fused rings, bridged rings, or spirocyclic) systems of saturated or partially unsaturated hydrocarbons. Examples of cyclic hydrocarbon groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, 1,2,3,4-tetrahydronaphthyl, and adamantyl. In the case of polycyclic cyclic hydrocarbon groups, only one ring in the cyclic hydrocarbon group needs to be non-aromatic.
[0036] As used herein, the term "heterocyclic hydrocarbon group" refers to a saturated or partially unsaturated 3-8 membered monocyclic, 7-12 membered bicyclic (fused, bridged, or spirocyclic), or 11-14 membered tricyclic (fused, bridged, or spirocyclic) ring system having one or more heteroatoms (such as O, N, S, P, or Se), for example, 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or for example, 1, 2, 3, 4, 5, or 6 heteroatoms, said heteroatoms being independently selected from nitrogen, oxygen, and sulfur, unless otherwise stated. Examples of heterocyclic hydrocarbon groups include, but are not limited to, piperidinyl, piperazinyl, pyrrolyl, dioxazolidinyl, tetrahydrofuranyl, isoindololinyl, indololinyl, imidazoalkyl, pyrazolyl, oxazolyl, isoxazolyl, triazolyl, oxacyclopropyl, aziridine, oxacyclobutyl, thiohexacyclobutyl, 1,2,3,6-tetrahydropyridinyl, tetrahydropyranyl, dihydropyranyl, pyranyl, morpholinyl, tetrahydrothiaranyl, 1,4-diazacycloheptyl, 1,4-oxazacycloheptyl, 2-oxa-5- Azabicyclo[2.2.1]heptyl, 2,5-diazabicyclo[2.2.1]heptyl, 2-oxa-6-azaspiro[3.3]heptyl, 2,6-diazaspiro[3.3]heptyl, 1,4-dioxa-8-azaspiro[4.5]decyl, 1,4-dioxaspiro[4.5]decyl, 1-oxaspiro[4.5]decyl, 1-azaspiro[4.5]decyl, 3'H-spiro[cyclohexane-1,1'-isobenzofuran]-yl, 7'H-spiro[cyclohexane-1,5 '-furano[3,4-b]pyridinyl]-yl, 3'H-spiro[cyclohexane-1,1'-furano[3,4-c]pyridinyl]-yl, 3-azabicyclo[3.1.0]hexyl, 3-azabicyclo[3.1.0]hexane-3-yl, 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazolyl, 3,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidinyl, 4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridinyl, 5,6,7,8- Tetrahydropyrido[4,3-d]pyrimidinyl, 2-azaspiro[3.3]heptyl, 2-methyl-2-azaspiro[3.3]heptyl, 2-azaspiro[3.5]nonyl, 2-methyl-2-azaspiro[3.5]nonyl, 2-azaspiro[4.5]decyl, 2-methyl-2-azaspiro[4.5]decyl, 2-oxa-azaspiro[3.4]octyl, 2-oxa-azaspiro[3.4]octane-6-yl, 5,6-dihydro-4H-cyclopentadien[b]thiophene, etc. In the case of polycyclic heterocyclic alkyl groups, only one ring in the heterocyclic alkyl group needs to be non-aromatic (e.g., 4,5,6,7-tetrahydrobenzo[c]isoxazolyl).
[0037] It should be understood that when a variable has two connections with the remainder of the formula of the compound, these two connections can be at the same atom or different atoms of the variable. For example, when a variable (e.g., variable X) is a cycloalkyl or heterocycloalkyl and has two connections with the remainder of the formula of the compound, these two connections can be at the same atom or different atoms of the cycloalkyl or heterocycloalkyl.
[0038] As used herein, the term "aryl" includes aromatic groups, including "conjugated" or polycyclic systems having one or more aromatic rings and containing no heteroatoms in the ring structure. The term aryl includes both monovalent and divalent groups. Examples of aryl groups include, but are not limited to, phenyl, biphenyl, naphthyl, etc. Conveniently, aryl is phenyl.
[0039] As used herein, the term "heteroaryl" is intended to include stable 5-, 6-, or 7-membered monocyclic or 7-, 8-, 9-, 10-, 11-, or 12-membered bicyclic aromatic heterocycles, the ring consisting of a carbon atom and one or more heteroatoms, for example, 1 or 1-2 or 1-3 or 1-4 or 1-5 or 1-6 heteroatoms, or for example, 1, 2, 3, 4, 5, or 6 heteroatoms, the heteroatoms being independently selected from nitrogen, oxygen, and sulfur. The nitrogen atom may be substituted or unsubstituted (i.e., N or NR, where R is H or another substituent as defined). The nitrogen and sulfur heteroatoms may optionally be oxidized (i.e., N...). O and S(O) p (where p=1 or 2). It should be noted that the total number of S and O atoms in an aromatic heterocycle does not exceed one. Examples of heteroaryl groups include pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetraazole, pyrazole, oxazole, isoxazole, isothiazole, pyridine, pyrazine, pyridazine, pyrimidine, etc. Heteroaryl groups can also be fused or bridged with non-aromatic alicyclic or heterocyclic groups to form polycyclic systems (e.g., 4,5,6,7-tetrahydrobenzo[c]isooxazolyl). In some embodiments, the heteroaryl group is thiophene or benzothiophene. In some embodiments, the heteroaryl group is thiophene. In some embodiments, the heteroaryl group is benzothiophene.
[0040] In addition, the terms "aryl" and "heteroaryl" include polycyclic aryl and heteroaryl, such as tricyclic and bicyclic, such as naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazolium, benzothiophene, quinoline, isoquinoline, naphthrydine, indole, benzofuran, purine, benzofuran, denitropurine, and indazine.
[0041] The cyclic hydrocarbon group, heterocyclic hydrocarbon group, aryl or heteroaryl ring may be substituted at one or more ring positions (e.g., the carbon or heteroatom forming the ring, such as N) with substituents such as those described above, such as alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylic acid ester, alkyl carbonyl, alkylamino carbonyl, aralkylamino carbonyl, alkenylamino carbonyl, alkyl carbonyl, aryl carbonyl, aralkyl carbonyl, alkenyl carbonyl, alkoxy carbonyl, amino carbonyl, alkyl thiocarbonyl, phosphate ester, phosphonate ester (phosphonato), phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and urea), amido, imino, mercapto, alkylthio, arylthio, thiocarbamate, sulfate, alkylsulfinyl, sulfonato, aminosulfonyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclic, alkylaryl, or aromatic or heteroaromatic moieties. Aryl and heteroaryl groups can also be fused or bridged with non-aromatic alicyclic or heterocyclic groups to form polycyclic systems (e.g., tetrahydronaphthalene, methylenedioxyphenyl such as benzo[d][1,3]dioxacyclopenten-5-yl).
[0042] As used herein, the term "substituted" means that any one or more hydrogen atoms on a specified atom are replaced by an option of a specified group, provided that the substitution does not exceed the normal valence of the specified atom and that the substitution produces a stable compound. When the substituent is an oxo or ketone (i.e., =O), then two hydrogen atoms on the atom are replaced. Keto substituents are not present on aromatic moieties. Cyclic double bonds as used herein are double bonds formed between two adjacent ring atoms (e.g., C=C, C=N, or N=N). "Stable compound" and "stable structure" are intended to mean a compound that is robust enough to withstand separation from the reaction mixture to a useful purity and formulation into an effective therapeutic agent.
[0043] When the bond to a substituent is shown to be an intersecting bond with two atoms in the linking ring, then such a substituent can bond to any atom in the ring. When a substituent is listed without specifying which atom it bonds to the rest of the compound in the given formula, then such a substituent can bond to any atom in the formula. Combinations of substituents and / or variables are permitted, provided that such combinations produce a stable compound.
[0044] When any variable (e.g., R) appears more than once in any component or formula of a compound, its definition for each occurrence is independent of its definition for every other occurrence. Thus, for example, if a group is shown to be substituted by 0-2 R moieties, then that group may optionally be substituted by at most two R moieties, and R is independently selected from the definition of R each time it appears. Furthermore, combinations of substituents and / or variables are permitted, provided that such combinations produce a stable compound.
[0045] The term "hydroxyl" or "hydroxyl" as used herein includes those having -OH or -O - . group.
[0046] The term “halogenated” or “halogen” as used in this article refers to fluorine, chlorine, bromine, and iodine.
[0047] The terms “halogenated alkyl” or “halogenated alkoxy” refer to alkyl or alkoxy groups that are substituted with one or more halogen atoms.
[0048] As used herein, the term "optionally substituted haloalkyl" means an unsubstituted haloalkyl or a haloalkyl having a specified substituent that replaces one or more hydrogen atoms on one or more carbon atoms of the hydrocarbon backbone. Such substituents may include, for example, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkyl carboxyloxy, aryl carboxyloxy, alkoxy carboxyloxy, aryloxy carboxyloxy, carboxylic acid ester, alkyl carbonyl, aryl carbonyl, alkoxy carbonyl, amino carbonyl, alkyl amino carbonyl, dialkyl amino carbonyl, alkyl thiocarbonyl, alkoxy, phosphate ester, phosphonato, phosphinato, amino (including alkyl amino, dialkyl amino, aryl amino, diaryl amino and alkyl aryl amino), acyl amino (including alkyl carbonyl amino, aryl carbonyl amino, carbamoyl and urea), amido, imino, mercapto, alkyl thio, aryl thio, thiocarbamate, sulfate, alkyl sulfinyl, sulfonato, aminosulfonyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclic, alkyl aryl or aromatic or heteroaromatic moiety.
[0049] As used herein, the term "alkoxy" or "alkoxyl" includes substituted and unsubstituted alkyl, alkenyl, and alkynyl groups covalently attached to an oxygen atom. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, isopropoxy, propoxy, butoxy, and pentoxy. Examples of substituted alkoxy groups include haloalkoxy groups. The alkoxy group may be substituted with groups such as alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylic acid ester, alkyl carbonyl, aryl carbonyl, alkoxy carbonyl, amino carbonyl, alkylamino carbonyl, dialkylamino carbonyl, alkyl thiocarbonyl, alkoxy, phosphate ester, phosphonato, phosphinato, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and urea), amido, imino, mercapto, alkylthio, arylthio, thiocarbamate, sulfate, alkylsulfinyl, sulfonato, aminosulfonyl, sulfonamide, nitro, trifluoromethyl, cyano, azide, heterocyclic, alkylaryl or aromatic or heteroaromatic moiety. Examples of halogen-substituted alkoxy groups include, but are not limited to, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, and trichloromethoxy.
[0050] The expressions “one or more of A, B or C”, “one or more A, B or C”, “one or more of A, B and C”, “one or more A, B and C”, “choose from the group consisting of A, B and C”, “select from A, B and C”, etc., used interchangeably in this document, and all mean an option from the group consisting of A, B and / or C, that is, one or more A, one or more B, one or more C or any combination thereof, unless otherwise indicated.
[0051] It should be understood that this disclosure provides methods for synthesizing compounds of any formula described herein. This disclosure also provides detailed methods for synthesizing the various disclosed compounds according to the following schemes and those shown in the examples.
[0052] It should be understood that throughout this specification, when a composition is described as having, including, or comprising specific components, it is assumed that the composition is also substantially composed of or consisting of the listed components. Similarly, when a method or process is described as having, including, or comprising specific process steps, the process is also substantially composed of or consisting of the listed processing steps. Furthermore, it should be understood that the order of the steps or the sequence of certain actions is not important, as long as the invention remains operable. Moreover, two or more steps or actions may be performed simultaneously.
[0053] It should be understood that the synthetic methods of this disclosure can allow for a variety of functional groups, and therefore a wide range of substituted starting materials can be used. The methods typically provide the desired final compound at or near the end of the process, although it may be desirable in some cases to further convert the compound into its pharmaceutically acceptable salt.
[0054] It should be understood that the compounds of this disclosure can be prepared in various ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates using standard synthetic methods and procedures known to those skilled in the art, or readily apparent to those skilled in the art based on the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules, as well as for functional group transformations and manipulations, are available from relevant scientific literature or standard textbooks in the field. While not limited to any one or more sources, classic texts such as Smith, MB, March, J., March... 's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure , 5th edition, John Wiley & Sons: New York, 2001; Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis , 3rd ed., John Wiley& Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations , VCHPublishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis John Wiley and Sons (1994); and L. Paquette, eds. Encyclopedia of Reagents for Organic Synthesis John Wiley and Sons (1995) (incorporated hereby cited) is a useful and well-regarded reference textbook on organic synthesis known to those skilled in the art.
[0055] Those skilled in the art will notice that the order of certain steps, such as the introduction and removal of protecting groups, can be altered in the reaction sequence and synthetic scheme described herein. They will also recognize that certain groups may require protection from the effects of reaction conditions. Protecting groups can also be used to distinguish similar functional groups within a molecule. A list of protecting groups and how to introduce and remove them can be found in Greene, TW, Wuts, PGM. Protective Groups in Organic Synthesis, 3rd ed., John Wiley & Sons: NewYork, 1999.
[0056] It should be understood that, unless otherwise stated, any description of a treatment or prevention method includes the use of the said compound to provide such treatment or prevention, as described herein. It should be further understood that, unless otherwise stated, any description of a treatment or prevention method includes the use of the said compound to prepare a medicament for treating or preventing such a condition. The treatment or prevention includes treating or preventing human or non-human animals, including rodents and other disease models.
[0057] It should be understood that, unless otherwise stated, any description of a treatment method includes the use of the said compounds to provide such treatment, as described herein. It should be further understood that, unless otherwise stated, any description of a treatment method includes the use of the said compounds to prepare a drug for treating such a condition. The treatment includes treating human or non-human animals, including rodents and other disease models.
[0058] As used herein, the term "object" includes humans and non-human animals, as well as cell lines, cell cultures, tissues, and organs. In some embodiments, the object is a mammal. The mammal may be, for example, a human or a suitable non-human mammal, such as a primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep, or pig. The object may also be a bird or poultry. In some embodiments, the object is a human.
[0059] As used herein, the term "subject with need" refers to a subject suffering from a disease or subject with an increased risk of developing a disease. A subject with need may be a subject previously diagnosed or identified as having a disease or disorder disclosed herein. A subject with need may also be a subject suffering from a disease or disorder disclosed herein. Alternatively, a subject with need may be a subject with an increased risk of developing such a disease or disorder relative to the general population (i.e., a subject predisposed to developing such a disorder relative to the general population). A subject with need may suffer from a treatment-resistant or resistant disease or disorder disclosed herein (i.e., a disease or disorder disclosed herein that is unresponsive to treatment or has not yet responded to treatment). The subject may be resistant at the start of treatment or may become resistant during treatment. In some embodiments, the subject with need has received all known effective therapies for the disease or disorder disclosed herein and failed. In some embodiments, the subject with need has received at least one prior therapy.
[0060] As used herein, the term “treatment” describes the management and care of a patient in order to combat a disease, condition, or disorder, and includes the administration of compounds of this disclosure or their pharmaceutically acceptable salts, polymorphs, or solvates to alleviate or eliminate symptoms or complications of the disease, condition, or disorder. The term “treatment” may also include treatment of in vitro cell or animal models. It should be understood that references to “treatment” include the relief of existing symptoms of a condition. Thus, “treatment” for a state, disorder, or disorder includes: (1) preventing or delaying the onset of clinical symptoms of a state, disorder, or disorder in a person who may have or is susceptible to the state, disorder, or disorder but has not yet experienced or displayed clinical or subclinical symptoms of the state, disorder, or disorder; (2) suppressing the state, disorder, or disorder, i.e., preventing, reducing, or delaying the development of the disease or its recurrence (in the case of maintenance treatment) or at least one of its clinical or subclinical symptoms; or (3) alleviating or reducing the disease, i.e., causing the disappearance of at least one of the state, disorder, or disorder or its clinical or subclinical symptoms.
[0061] It should be understood that the compounds of this disclosure or their pharmaceutically acceptable salts, polymorphs or solvates may or may not be used for the prevention of related diseases, symptoms or disorders, or for the identification of suitable candidates for such purposes.
[0062] The terms “prevention,” “stopping,” or “protection from” used in this article describe reducing or eliminating the onset of symptoms or complications of such a disease, condition, or disorder.
[0063] It should be understood that those skilled in the art may refer to general reference texts for a detailed description of the known or equivalent techniques discussed herein. These texts include Ausubel et al. Current Protocols in Molecular Biology John Wiley and Sons, Inc. (2005); Sambrook et al. Molecular Cloning, A Laboratory Manual (3rd ed.), Cold Spring Harbor Press, Cold Spring Harbor, NewYork (2000); Coligan et al., Current Protocols in Immunology , John Wiley & Sons,NY; Enna et al., Current Protocols in Pharmacology John Wiley & Sons, NY; Fingle et al. The Pharmacological Basis of Therapeutics (1975), Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, 18th edition (1990). Of course, these texts may also be referenced when making or using any aspect of this disclosure.
[0064] It should be understood that this disclosure also provides pharmaceutical compositions comprising any of the compounds described herein and at least one pharmaceutically acceptable excipient or carrier.
[0065] As used herein, the term "pharmaceutical composition" refers to a formulation containing the compounds of this disclosure, in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or unit dosage form. Unit dosage form can be any of a variety of forms, including, for example, capsules, intravenous infusion bags, tablets, a single pump on an aerosol inhaler, or a tubular bottle. The amount of active ingredient (e.g., a formulation of the disclosed compound or its salts, hydrates, solvates, or isomers) in a unit dosage composition is an effective amount and varies depending on the specific treatment involved. Those skilled in the art will understand that, depending on the patient's age and condition, it may sometimes be necessary to make routine variations in dosage. Dosage will also depend on the route of administration. A variety of routes are considered, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, sublingual, sublingual, intrapleural, intrathecal, intranasal, etc. Dosage forms for topical or transdermal application of the compounds used in this disclosure include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and with any desired preservatives, buffers, or propellants.
[0066] As used herein, the term "pharmaceutically acceptable" means a compound, anion, cation, material, composition, carrier, and / or dosage form that, to a reasonable extent of medical judgment, is suitable for contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications, in proportion to a reasonable benefit / risk ratio.
[0067] As used herein, the term "pharmaceuticalally acceptable excipient" refers to an excipient that can be used to prepare a pharmaceutical composition that is generally safe, non-toxic, and not biologically or otherwise undesirable, and includes excipients acceptable for both veterinary and human pharmaceutical applications. As used in this specification and claims, "pharmaceuticalally acceptable excipient" includes one or more such excipients.
[0068] It should be understood that the pharmaceutical compositions of this disclosure are formulated to be compatible with their intended route of administration. Examples of routes of administration include parenteral, such as intravenous, intradermal, subcutaneous, oral (e.g., ingestion), inhalation, transdermal (topical), and transmucosal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous application may include the following components: sterile diluents such as water for injection, saline solution, non-volatile oils, polyethylene glycol, glycerol, propylene glycol, or other synthetic solvents; antibacterial agents such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates, or phosphates; and agents for adjusting the pH such as sodium chloride or dextrose. The pH may be adjusted with an acid or base (such as hydrochloric acid or sodium hydroxide). Parenteral preparations may be packaged in ampoules, disposable syringes, or multiple-dose tubular vials made of glass or plastic.
[0069] It should be understood that the compounds or pharmaceutical compositions of this disclosure can be administered to the subject using many well-known methods currently used for chemotherapeutic treatments. For example, the compounds of this disclosure can be injected into the bloodstream or body cavity, administered orally, or applied through the skin as a patch. The selected dose should be sufficient to constitute an effective treatment, but not high enough to cause unacceptable side effects. The condition of the disease (e.g., the disease or disorder disclosed herein) and the patient's health should preferably be closely monitored during treatment and for a reasonable period after treatment.
[0070] As used herein, the term "therapeutic effective amount" refers to the amount of a pharmaceutical agent used to treat, improve, or prevent an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. This effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend on the subject's weight, body type, and health; the nature and severity of the condition; and the therapeutic agent or combination of therapeutic agents chosen for administration. A therapeutically effective amount for a given situation can be determined through routine experiments within the skill and judgment of a clinician.
[0071] As used herein, the term "therapeutic effective amount" refers to the amount of a pharmaceutical agent used to treat or improve an identified disease or condition, or to exhibit a detectable therapeutic or inhibitory effect. This effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend on the subject's weight, body type, and health; the nature and severity of the condition; and the therapeutic agent or combination of therapeutic agents chosen for administration. A therapeutic effective amount for a given situation can be determined through routine experiments within the skill and judgment of a clinician.
[0072] It should be understood that for any compound, the therapeutically effective dose can initially be estimated in a cell culture assay (e.g., a culture assay of proliferative cells) or in an animal model (typically rat, mouse, rabbit, dog, or pig). The animal model can also be used to determine the appropriate concentration range and route of administration. This information can then be used to determine the useful dose and route of administration in humans. Therapeutic / prophylactic efficacy and toxicity, e.g., ED, can be determined using standard pharmaceutical procedures in cell culture or laboratory animals. 50 (the therapeutically effective dose in 50% of the population) and LD 50 (The dose that would be lethal to 50% of the population). The dose ratio between toxic effects and therapeutic effects is the therapeutic index, which can be expressed as the ratio LD50. 50 / ED 50 Pharmaceutical compositions exhibiting a high therapeutic index are preferred. Dosage can vary within this range, depending on the dosage form used, patient sensitivity, and route of administration.
[0073] Adjust the dosage and administration to provide adequate levels of active agent or maintain the desired effect. Factors to consider include the severity of the condition, the subject's general health, age, weight and sex, diet, timing and frequency of administration, drug combination, sensitivity to response, and tolerance / response to therapy. Depending on the half-life and clearance rate of the specific formulation, long-acting drug combinations may be administered every 3 to 4 days, weekly, or bi-weekly.
[0074] Pharmaceutical compositions containing the active compounds of this disclosure can be prepared in ways commonly known, such as by means of conventional mixing, dissolving, granulation, pelleting, grinding, emulsification, encapsulation, embedding, or lyophilization processes. Pharmaceutical compositions can be formulated in a conventional manner using one or more pharmaceutically acceptable carriers containing excipients and / or adjuvants that facilitate the processing of the active compound into articles suitable for pharmaceutical use. Of course, appropriate formulations depend on the chosen route of administration.
[0075] Suitable pharmaceutical compositions for injection include sterile aqueous solutions (in the water-soluble case) or dispersions, and sterile powders for immediate preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, antibacterial water, and Cremophor EL. (BASF, Parsippany, NJ) or phosphate-buffered saline (PBS). In all cases, the composition must be sterile and should be fluid enough to be easily injected. It must be stable under the conditions of preparation and storage and must be preserved from contamination by microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.), and suitable mixtures thereof. Suitable fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size (in the case of dispersions), and by using surfactants. Inhibition of microbial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferred to include isotonic agents in the composition, such as sugars, polyols such as mannitol and sorbitol, and sodium chloride. The absorption of the injectable composition can be prolonged by including agents that delay absorption, such as aluminum monostearate and gelatin.
[0076] Sterile injectable solutions can be prepared by incorporating the desired amount of the active compound, along with one or more of the components listed above, into a suitable solvent, followed by filtration and sterilization. Dispersions are typically prepared by incorporating the active compound into a sterile medium containing a base dispersion medium and any other desired components from those listed above. For sterile powders used to prepare sterile injectable solutions, preparation methods include vacuum drying and freeze-drying, which produce a powder containing the active ingredient plus any other desired components from its previously sterile filtered solution.
[0077] Oral compositions typically include an inert diluent or an edible, pharmaceutically acceptable carrier. They may be encapsulated in gelatin capsules or compressed into tablets. For oral therapeutic administration, the active compound may be mixed with excipients and administered in the form of tablets, lozenges, capsules, or sacs. Oral compositions may also be prepared using a liquid carrier for use as a mouthwash, wherein the compound in the fluid carrier is administered orally and by rinsing and spitting or swallowing. Pharmaceutically compatible binders and / or excipients may be included as part of the composition. The tablets, pills, capsules, lozenges, etc., may contain any of the following components or compounds with similar properties: binders such as microcrystalline cellulose, tragacanth gum, or gelatin; excipients such as starch or lactose; disintegrants such as alginate, Primogel, or corn starch; lubricants such as magnesium stearate or sterotes; gliding agents such as colloidal silica; sweeteners such as sucrose or saccharin; or flavoring agents such as peppermint, methyl salicylate, or orange flavoring.
[0078] For administration by inhalation, the compound is delivered in the form of an aerosol spray from a pressurized container or dispenser (containing a suitable propellant, such as a gas such as carbon dioxide) or a sprayer.
[0079] Systemic application can also be via transmucosal or transdermal routes. For transmucosal or transdermal application, a penetrant suitable for the barrier to be penetrated is used in the formulation. Such penetrants are generally known in the art and include, for example, detergents, bile salts, and fusidic acid derivatives for transmucosal application. Transmucosal application can be accomplished by using nasal sprays, powders, or suppositories. For transdermal application, the active compound is formulated into ointments, creams, gels, or lotions generally known in the art.
[0080] Active compounds can be prepared with pharmaceutically acceptable carriers that protect the compounds from rapid elimination from the body, such as controlled-release formulations, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers such as ethylene-vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. Methods for preparing such formulations will be understood by those skilled in the art. These materials are also commercially available from Alza Corporation and Nova Pharmaceuticals, Inc. Liposome suspensions (including liposomes targeting infected cells with monoclonal antibodies against viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.
[0081] Of particular advantage is that, for ease of administration and uniform dosage, oral or parenteral compositions are formulated in dosage units. The dosage unit form used herein refers to a physically discrete unit suitable as a unit dose for the object to be treated; each unit contains a predetermined amount of active compound, calculated to produce the desired therapeutic effect, in combination with the desired pharmaceutical carrier. The specifications of the dosage unit form of this disclosure depend on and are directly dependent on the unique characteristics of the active compound and the specific therapeutic effect to be achieved.
[0082] In therapeutic applications, the dosage of the pharmaceutical composition used according to this disclosure varies with the pharmaceutical agent, the age, weight, and clinical condition of the receiving patient, and the experience and judgment of the clinician or practitioner administering the therapy, among other factors affecting the selected dosage. Generally, the dosage should be sufficient to cause a slowing and preferably remission of the symptoms of the disease or disorder disclosed herein, and preferably also to cause complete remission of the disease or disorder. Dosages can range from about 0.01 mg / kg / day to about 5000 mg / kg / day. An effective amount of a pharmaceutical agent is the amount that provides an objectively identifiable improvement noticeable to a clinician or other qualified observer. Improvement in survival and growth indicates remission. As used herein, the term "dosage-effective manner" refers to the amount of active compound that produces the desired biological effect in the subject or cells.
[0083] It should be understood that the pharmaceutical composition may be included in a container, packet or dispenser together with the instructions for use.
[0084] It should be understood that all these forms are also considered within the scope of the claimed disclosure for compounds of this disclosure that are capable of further forming salts.
[0085] As used herein, the term "pharmaceutically acceptable salt" refers to a derivative of the compounds of this disclosure, wherein the parent compound is modified by preparing its acid or base salt. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines, and basic organic salts of acidic residues such as carboxylic acids. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of the parent compound, for example, formed from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, those derived from inorganic and organic acids selected from 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetate, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheponic acid, gluconic acid, glutamic acid, glycolic acid, hydroxyacetic acid, hydroxyacetaminophenarsic acid, hexylresorcinic acid, hydroabamic acid, hydrogen... Bromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthyl carboxylic acid, hydroxyethanesulfonic acid, lactic acid, lactobionic acid, lauryl sulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, napsylic acid, nitric acid, oxalic acid, primordial acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, hypoacetic acid, succinic acid, aminosulfonic acid, p-aminobenzenesulfonic acid, sulfuric acid, tannic acid, tartaric acid, toluenesulfonic acid, and common amino acids such as glycine, alanine, phenylalanine, and arginine.
[0086] In some embodiments, the pharmaceutically acceptable salt is a sodium salt, potassium salt, calcium salt, magnesium salt, diethylamine salt, choline salt, meglumine salt, N,N'-dibenzylethylenediamine salt (benzathine salt), tromethamine salt, ammonium salt, arginine salt, or lysine salt.
[0087] Other pharmaceutically acceptable examples of salts include hexanoic acid, cyclopentanepropionic acid, pyruvate, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-oct-2-en-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, mucoconic acid, etc. This disclosure also includes salts formed when the acidic proton present in the parent compound is replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth metal ion, or an aluminum ion); or salts formed when coordinated with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucosamine, etc. In salt form, it should be understood that the ratio of the compound to the cation or anion of the salt can be 1:1, or any ratio other than 1:1, such as 3:1, 2:1, 1:2, or 1:3.
[0088] It should be understood that all references to pharmaceutically acceptable salts include the same salt in its solvation form (solvent) or crystalline form (polymorph) as defined herein.
[0089] The compound or a pharmaceutically acceptable salt thereof may be administered orally, nasally, transdermally, pulmonaryly, by inhalation, sublingually, sublingually, intraperitoneally, subcutaneously, intramuscularly, intravenously, rectally, intrapleurally, intrathecally, or parenterally. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of certain routes of administration.
[0090] The dosing regimen for the compound is selected based on a number of factors, including the patient's type, species, age, weight, sex, and medical condition; the severity of the condition to be treated; the route of administration; the patient's renal and hepatic function; and the specific compound or its salt used. A general practitioner or veterinarian can readily determine and prescribe an effective amount of the drug required to prevent, counteract, or halt the progression of the disease.
[0091] For techniques used in formulating and applying the disclosed compounds, please refer to [link to relevant documentation]. Remington: the Science and Practice of Pharmacy, 19th edition, Mack Publishing Co., Easton, PA (1995). In one embodiment, the compounds described herein and their pharmaceutically acceptable salts are combined with a pharmaceutically acceptable carrier or diluent for use in a pharmaceutical article. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous organic solutions. The compounds will be present in such pharmaceutical compositions in an amount sufficient to provide the desired dose within the range described herein.
[0092] Unless otherwise stated, all percentages and ratios used herein are by weight. Other features and advantages of this disclosure will become apparent from the various embodiments. The provided embodiments illustrate different components and methods that can be used to practice this disclosure. The embodiments do not limit the claimed disclosure. Based on this disclosure, those skilled in the art can identify and employ other components and methods that can be used to practice this disclosure.
[0093] In the synthetic schemes described herein, compounds may be drawn using a specific configuration for simplicity. Such a specific configuration should not be construed as limiting the disclosure to one or more isomers, tautomers, positional isomers, or stereoisomers, nor does it exclude mixtures of isomers, tautomers, positional isomers, or stereoisomers; however, it should be understood that a given isomer, tautomer, positional isomer, or stereoisomer may have a higher level of activity than another isomer, tautomer, positional isomer, or stereoisomer.
[0094] All publications and patent documents cited herein are incorporated herein by reference as if each such publication or document were expressly and individually identified as incorporated herein by reference. The citation of publications and patent documents is not intended to acknowledge that any of them is prior art, nor does it constitute any admission of their content or date. The invention has now been described in writing, and those skilled in the art will recognize that the invention can be practiced in a variety of embodiments, and that the foregoing description and the following examples are for illustrative purposes and not for limiting the scope of the following claims.
[0095] As used herein, the phrase "compounds of this disclosure" refers to those compounds disclosed herein, both generally and specifically.
[0096] The compounds disclosed herein In some respects, this disclosure provides compounds of formula (I'): (I'); Or its pharmaceutically acceptable salt, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; n is an integer in the range of 0 to 3; R a and R b Each of the following is independently H, halogen, -CN, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, wherein the -O(C1-C6 alkyl), -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally influenced by one or more R S Replace; or R a and R b Together with the atoms they are attached to, they form a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group, wherein the C3-C7 cyclic hydrocarbon group or the 3- to 7-membered heterocyclic hydrocarbon group is optionally surrounded by one or more R S replace; Each R S It is independently a halogen, -CN, -OH, -O (C1-C6 alkyl), -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C1-C6 haloalkyl; Z is either -O- or -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -OH, -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -SH, -S (C1-C6 alkyl), -S (C6-C 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 -NH (3- to 7-membered heterocyclic hydrocarbon group), wherein -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -S (C1-C6 alkyl), -S (C6-C6 alkyl)2, -NH (C1-C6 alkyl)2, -NH ... 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace; Each R 1S Independently, it is an oxo, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -S(C1-C6 alkyl), -SO2(C1-C6 alkyl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C7 cycloalkyl, or 3- to 7-membered heterocyclic alkyl group; Ar1 is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A1 replace; Each R A1 Independently, it is Ar2, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T either does not exist or is Ar2; Each Ar2 is independently C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 Replace; and Each R A2It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0097] In some respects, this disclosure provides compounds of formula (I): (I); Or its pharmaceutically acceptable salt, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl))nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; n is an integer in the range of 0 to 3; Z is either -O- or -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -OH, -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -SH, -S (C1-C6 alkyl), -S (C6-C 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 -NH (3- to 7-membered heterocyclic hydrocarbon group), wherein -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -S (C1-C6 alkyl), -S (C6-C6 alkyl)2, -NH (C1-C6 alkyl)2, -NH ... 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10(cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace; Each R 1S Independently, it is an oxo, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -S(C1-C6 alkyl), -SO2(C1-C6 alkyl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C7 cycloalkyl, or 3- to 7-membered heterocyclic alkyl group; Ar1 is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A1 replace; Each R A1 Independently, it is Ar2, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T either does not exist or is Ar2; Each Ar2 is independently C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 Replace; and Each R A2 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0098] In some respects, this disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; n is an integer in the range of 0 to 3; Z is either -O- or -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon, -NH-(C3-C 10 -NH-(3- to 7-membered heterocyclic hydrocarbon group) or -NH-(3- to 7-membered heterocyclic hydrocarbon group), wherein -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon group, -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace; Each R 1S It is independently a halogen, -CN, -OH, or C1-C6 alkoxy group; Ar1 is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A1 replace; Each R A1 Independently, it is Ar2, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T either does not exist or is Ar2; Each Ar2 is independently C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 Replace; and Each R A2 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0099] In some respects, this disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)- or C1-C6 alkyl; L is absent or is a C1-C6 alkyl group; Y is -O- or C1-C6 alkyl; n is an integer in the range of 0 to 3; Z is -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is a C1-C6 alkyl group; Ar1 is a C6-C that is optionally replaced by one or more Ar2. 10 Aryl; T either does not exist or is Ar2; and Each Ar2 is independently C6-C 10 Aryl.
[0100] In some respects, this disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)- or C1-C6 alkyl; L is absent or is a C1-C6 alkyl group; Y is -O- or C1-C6 alkyl; n is an integer in the range of 0 to 3; Z is -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is a C1-C6 alkyl group; Ar1 is C6-C 10 Aryl; T is C6-C 10 Aryl.
[0101] In some respects, this disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)- or C1-C6 alkyl; L is absent or is a C1-C6 alkyl group; Y is -O- or C1-C6 alkyl; n is an integer in the range of 0 to 3; Z is -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is a C1-C6 alkyl group; Ar1 is optionally construed by one or more C6-C 10 Aryl-substituted C6-C 10 Aryl; and T does not exist.
[0102] In some respects, this disclosure provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)- or C1-C6 alkyl; L is absent or is a C1-C6 alkyl group; Y is -O- or C1-C6 alkyl; n is 2; Z is -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon, -NH-(C3-C 10 -NH-(3- to 7-membered heterocyclic hydrocarbon group), wherein -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon group, -NH-(C3 ... -NH-(C1-C6 alkyl)2, 5- to 10-membered heteroaryl, -NH-(C1-C6 alkyl)2, 5- to 10-membered heteroaryl, -NH-(C1-C6 alkyl)2, 5- 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S Substitution and C1-C6 alkyl groups are formed by one or more R 1S replace; Each R 1S Independently, it is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -S(C1-C6 alkyl), -SO2(C1-C6 alkyl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C7 cycloalkyl or 3- to 7-membered heterocyclic alkyl group; Ar1 is optionally defined by one or more R A1 Replacement C6-C 10 Aryl; Each R A1 Independently, it is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T is Ar2; Ar2 is optionally defined by one or more R A2 Replacement C6-C 10 Aryl; and Each R A2 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0103] It should be understood that, for the compounds described in this disclosure, the variables X, L, nl, Y, n, R... a R b Z, R Z R1, R 1S Ar1, R A1 T, Ar2 and R A2 Each can be selected (where applicable) from the groups described herein, and the variables X, L, nl, Y, n, R are used in this document. a R b Z, R Z R1, R 1S Ar1, R A1 T, Ar2 and R A2 Any group described in any of the above can (where applicable) be related to the variables X, L, nl, Y, n, R in this document. a R b Z, R Z R1, R 1S Ar1, R A1 T, Ar2 and R A2 Any combination of one or more of the remaining groups described in the text.
[0104] VARIABLE X In some embodiments, X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0105] In some implementations, X is -O-.
[0106] In some embodiments, X is -NH- or -N(C1-C6 alkyl)-, wherein the -N(C1-C6 alkyl)- is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0107] In some implementations, X is -NH-.
[0108] In some embodiments, X is -N(C1-C6 alkyl)-, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0109] In some embodiments, X is -N(C1-C6 alkyl)- which is optionally substituted with one or more halogens or -OH.
[0110] In some embodiments, X is optionally a -N (C1-C6 alkyl)- substituted with one or more F or -OH.
[0111] In some embodiments, X is -N(C1-C6 alkyl)-.
[0112] In some implementations, X is -N(CH3)-.
[0113] In some embodiments, X is -N(C1-C6 alkyl)- substituted with one or more halogens or -OH.
[0114] In some embodiments, X is a -N (C1-C6 alkyl)- substituted with one or more F or -OH.
[0115] In some embodiments, X is a -N (C1-C6 alkyl)- substituted with at least one F and at least one -OH.
[0116] In some embodiments, X is a -N (C1-C6 alkyl)- substituted with one to three F and one -OH.
[0117] In some embodiments, X is a C1-C6 alkyl, C3-C8 cyclic hydrocarbon, or C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0118] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl), which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy groups.
[0119] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl), which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0120] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl) optionally substituted with one or more halogens (e.g., F).
[0121] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl) optionally substituted with one or more C1-C6 haloalkyl groups.
[0122] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl) optionally substituted with one or more C1-C6 alkoxy groups.
[0123] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl).
[0124] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy groups.
[0125] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0126] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl) substituted with one or more halogens (e.g., F).
[0127] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl) substituted with one or more C1-C6 haloalkyl groups.
[0128] In some embodiments, X is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl) substituted with one or more C1-C6 alkoxy groups.
[0129] In some embodiments, X is a C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the C3-C8 cyclic hydrocarbon group, C6-C 10The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0130] In some embodiments, X is a C3-C8 cyclic hydrocarbon group (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl) which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy.
[0131] In some embodiments, X is a C3-C8 cyclic hydrocarbon group (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl).
[0132] In some embodiments, X is a C3-C8 cyclic hydrocarbon group (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy.
[0133] In some implementations, X is C6-C 10 Aryl group, optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0134] In some implementations, X is C6-C 10 Aryl.
[0135] In some embodiments, X is a C6-C alkyl group substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy groups. 10 Aryl.
[0136] In some embodiments, X is a 3- to 8-membered heterocyclic hydrocarbon group (e.g., aziridine, pyrrolidinyl, or piperidinyl), which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy.
[0137] In some embodiments, X is a 3- to 8-membered heterocyclic hydrocarbon group (e.g., azirrobutyl, pyrrolidinyl, or piperidinyl).
[0138] In some embodiments, X is a 3- to 8-membered heterocyclic hydrocarbon group (e.g., aziridine, pyrrolidinyl, or piperidinyl) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy.
[0139] In some embodiments, X is a azircyclic butyl (e.g., or ), which may optionally be substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0140] In some embodiments, X is a azircyclic butyl (e.g., or ).
[0141] In some embodiments, X is a nitrogen-containing heterocyclic butyl group substituted with one or more halogens, -CN, -OH, -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy groups (e.g., or ).
[0142] In some embodiments, X is a 5- to 10-membered heteroaryl group, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0143] In some implementations, X is a 5- to 10-membered heteroaryl group.
[0144] In some embodiments, X is a 5- to 10-membered heteroaryl group substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy.
[0145] Variables L and nl In some implementations, L is absent.
[0146] In some embodiments, L is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl-、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0147] In some implementations, L is -O-.
[0148] In some embodiments, L is -NH- or -N(C1-C6 alkyl)-, wherein the -N(C1-C6 alkyl)- is optionally replaced by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl)2 or -N(C1-C6 alkyl)2.
[0149] In some implementations, L is -NH-.
[0150] In some embodiments, L is -N(C1-C6 alkyl)-, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl)2 or -N(C1-C6 alkyl)2.
[0151] In some embodiments, L is -N(C1-C6 alkyl)-.
[0152] In some embodiments, L is -N(C1-C6 alkyl)- substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl)2 or -N(C1-C6 alkyl)2.
[0153] In some embodiments, L is C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O).nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl - wherein the C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0154] In some embodiments, L is a C1-C6 alkyl or C2-C6 alkenyl group, wherein the C1-C6 alkyl or C2-C6 alkenyl group is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl)2, or -N(C1-C6 alkyl)2.
[0155] In some embodiments, L is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl), which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0156] In some embodiments, L is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl).
[0157] In some embodiments, L is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0158] In some embodiments, L is a C2-C6 alkenyl group, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0159] In some implementations, L is a C2-C6 alkenyl group.
[0160] In some embodiments, L is a C2-C6 alkenyl group substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0161] In some embodiments, L is -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl - wherein the -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0162] In some embodiments, L is -((C1-C6 alkyl)-O) nl -or-(O-(C1-C6 alkyl)) nl - wherein the -((C1-C6 alkyl)-O) nl -or-(O-(C1-C6 alkyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0163] In some embodiments, L is -((C1-C6 alkyl)-O) nl -, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0164] In some embodiments, L is -((C1-C6 alkyl)-O) nl -
[0165] In some embodiments, L is -((C1-C6 alkyl)-O) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl)2, or -N(C1-C6 alkyl)2. nl -
[0166] In some embodiments, L is -(O-(C1-C6 alkyl)) nl -, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0167] In some embodiments, L is -(O-(C1-C6 alkyl)) nl -
[0168] In some embodiments, L is -(O-(C1-C6 alkyl)) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2. nl -
[0169] In some implementations, L is -((C2-C6 alkenyl)-O) nl -or-(O-(C2-C6 alkenyl)) nl -, wherein -((C2-C6 alkenyl)-O) nl -or-(O-(C2-C6 alkenyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0170] In some implementations, L is -((C2-C6 alkenyl)-O) nl -, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0171] In some implementations, L is -((C2-C6 alkenyl)-O) nl -
[0172] In some embodiments, L is -((C2-C6 alkenyl)-O) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2. nl -
[0173] In some implementations, L is -(O-(C2-C6 alkenyl)) nl -, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0174] In some implementations, L is -(O-(C2-C6 alkenyl)) nl -
[0175] In some embodiments, L is -(O-(C2-C6 alkenyl)) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2. nl -
[0176] In some embodiments, L is -((C1-C6 alkyl)-NH) nl -or-(NH-(C1-C6 alkyl)) nl - wherein -((C1-C6 alkyl)-NH) nl -or-(NH-(C1-C6 alkyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0177] In some embodiments, L is -((C1-C6 alkyl)-NH) nl -, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0178] In some embodiments, L is -((C1-C6 alkyl)-NH) nl -
[0179] In some embodiments, L is -((C1-C6 alkyl)-NH) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl)2, or -N(C1-C6 alkyl)2. nl -
[0180] In some embodiments, L is -(NH-(C1-C6 alkyl)) nl-, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0181] In some embodiments, L is -(NH-(C1-C6 alkyl)) nl -
[0182] In some embodiments, L is -(NH-(C1-C6 alkyl)) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2. nl -
[0183] In some embodiments, L is -((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0184] In some embodiments, L is -((C2-C6 alkenyl)-NH) nl -, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0185] In some embodiments, L is -((C2-C6 alkenyl)-NH) nl -
[0186] In some embodiments, L is -((C2-C6 alkenyl)-NH) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2. nl -
[0187] In some embodiments, L is -(NH-(C2-C6 alkenyl)) nl -, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0188] In some embodiments, L is -(NH-(C2-C6 alkenyl)) nl -
[0189] In some embodiments, L is -(NH-(C2-C6 alkenyl)) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2. nl -
[0190] In some implementations, nl is an integer in the range of 1 to 6.
[0191] In some implementations, nl is 6.
[0192] In some implementations, nl is an integer in the range of 1 to 5.
[0193] In some implementations, nl is 5.
[0194] In some implementations, nl is an integer in the range of 1 to 4.
[0195] In some implementations, nl is 4.
[0196] In some implementations, nl is an integer in the range of 1 to 3.
[0197] In some implementations, nl is 1. In some implementations, nl is 2. In some implementations, nl is 3.
[0198] variable Y In some embodiments, Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy.
[0199] In some implementations, Y is -O-.
[0200] In some embodiments, Y is -NH- or -N(C1-C6 alkyl)-, wherein the -N(C1-C6 alkyl)- is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0201] In some implementations, Y is -NH-.
[0202] In some embodiments, Y is -N(C1-C6 alkyl)-, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0203] In some embodiments, Y is -N(C1-C6 alkyl)-.
[0204] In some embodiments, Y is -N(C1-C6 alkyl)- substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0205] In some embodiments, Y is a C1-C6 alkyl or C2-C6 alkenyl, wherein the C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy.
[0206] In some embodiments, Y is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl), which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy groups.
[0207] In some embodiments, Y is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl).
[0208] In some embodiments, Y is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl) substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy groups.
[0209] In some embodiments, Y is a C2-C6 alkenyl group, which is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0210] In some implementations, Y is a C2-C6 alkenyl group.
[0211] In some embodiments, Y is a C2-C6 alkenyl group substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy.
[0212] Exemplary implementations of variables X, L, and Y In some embodiments, at most one of X and L is -O-, -NH-, or optionally substituted -N (C1-C6 alkyl)-.
[0213] In some embodiments, at most one of L and Y is -O-, -NH-, or optionally substituted -N (C1-C6 alkyl)-.
[0214] In some embodiments, at most one of X and Y is -O-, -NH-, or optionally substituted -N (C1-C6 alkyl)-.
[0215] In some embodiments, at most two of X, L and Y are -O-, -NH- or optionally substituted -N (C1-C6 alkyl)-.
[0216] In some embodiments, at most one of X, L and Y is -O-, -NH- or optionally substituted -N (C1-C6 alkyl)-.
[0217] In some embodiments, when X is -O-, -NH-, or optionally substituted -N(C1-C6 alkyl)- and Y is -O-, -NH-, or optionally substituted -N(C1-C6 alkyl)-, then L is not absent, -O-, -NH-, or optionally substituted -N(C1-C6 alkyl)-.
[0218] In some embodiments, X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cycloalkyl, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O)nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl - wherein the C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH (C1-C6 alkyl) or -N (C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; and Y is a C1-C6 alkyl or C2-C6 alkenyl group, wherein the C1-C6 alkyl or C2-C6 alkenyl group is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0219] In some embodiments, X is a C1-C6 alkyl, C3-C8 cyclic hydrocarbon, or C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl))nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH (C1-C6 alkyl) or -N (C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; and Y is a C1-C6 alkyl or C2-C6 alkenyl group, wherein the C1-C6 alkyl or C2-C6 alkenyl group is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0220] In some embodiments, X is a C1-C6 alkyl, C3-C8 cyclic hydrocarbon, or C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl-、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl - wherein the C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH (C1-C6 alkyl) or -N (C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; and Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy.
[0221] In some embodiments, X is -O-, -NH-, -N(C1-C6 alkyl)- or C1-C6 alkyl; L is absent or is C1-C6 alkyl; and Y is -O- or C1-C6 alkyl.
[0222] In some embodiments, X is -O-, -NH-, or -N(C1-C6 alkyl)-; L is C1-C6 alkyl; and Y is -O-.
[0223] In some embodiments, X is a C1-C6 alkyl group; L is absent; and Y is a C1-C6 alkyl group.
[0224] variable n In some implementations, n is an integer in the range of 0 to 3.
[0225] In some implementations, n is 0. In some implementations, n is 1. In some implementations, n is 2. In some implementations, n is 3.
[0226] variable Ra 、R b and R S In some implementations, R a and R b Each of the following is independently H, halogen, -CN, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, wherein the -O(C1-C6 alkyl), -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally influenced by one or more R S Replace; or R a and R b Together with the atoms they are attached to, they form a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group, wherein the C3-C7 cyclic hydrocarbon group or the 3- to 7-membered heterocyclic hydrocarbon group is optionally surrounded by one or more R S replace.
[0227] In some implementations, R a and R b One of them is H, and R a and R b One of them is a halogen, -CN, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, wherein the -O(C1-C6 alkyl), -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally represented by one or more R S Replace; or R a and R b Together with the atoms they are attached to, they form a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group, wherein the C3-C7 cyclic hydrocarbon group or the 3- to 7-membered heterocyclic hydrocarbon group is optionally surrounded by one or more R S replace.
[0228] In some implementations, R a It is H, and R bIt is a halogen, -CN, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 ynyl, wherein the -O(C1-C6 alkyl), -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 ynyl is optionally separated by one or more R S Replace; or R a and R b Together with the atoms they are attached to, they form a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group, wherein the C3-C7 cyclic hydrocarbon group or the 3- to 7-membered heterocyclic hydrocarbon group is optionally surrounded by one or more R S replace.
[0229] In some implementations, R a and R b Each is independently H or halogen; or R a and R b Together with the atoms they are attached to, they form a group optionally bounded by one or more R atoms. S Substituted C3-C7 cyclic hydrocarbon groups.
[0230] In some implementations, R a and R b Each is independently H or halogen; or R a and R b Together with the atoms they are attached to, they form C3-C7 cyclic hydrocarbon groups.
[0231] In some implementations, R a and R b Each is independently H or halogen; or R a and R b Together with the atoms they are attached to, they form a group optionally bounded by one or more R atoms. S Substituted cyclopropyl group.
[0232] In some implementations, R a and R b Each is independently H or halogen; or R a and R b Together with the atoms they are attached to, they form cyclopropyl groups.
[0233] In some implementations, R a and R b Each is either H or a halogen.
[0234] In some implementations, R a and R b At least one of them is H.
[0235] In some implementations, R a and R b One of them is H.
[0236] In some implementations, R a and R b Each is H.
[0237] In some implementations, R a and R b Each is a halogen on its own.
[0238] In some implementations, R a and R b Each is either F or Cl.
[0239] In some implementations, R a and R b At least one of them is a halogen.
[0240] In some implementations, R a and R b At least one of them is F or Cl.
[0241] In some implementations, R a and R b One of them is H, and R a and R b One of them is a halogen (e.g., F or Cl).
[0242] In some implementations, R a It is H, and R b It is a halogen (e.g., F or Cl).
[0243] In some implementations, R a and R b At least one of them is -CN, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 ynyl, wherein the -O(C1-C6 alkyl), -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 ynyl is optionally represented by one or more R S replace.
[0244] In some implementations, R a and R b At least one of them is -CN.
[0245] In some implementations, R a and R bAt least one of them is -OH or -O (C1-C6 alkyl), wherein the -O (C1-C6 alkyl) is optionally surrounded by one or more R S replace.
[0246] In some implementations, R a and R b At least one of them is -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2, wherein the -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2 is optionally separated by one or more R S replace.
[0247] In some implementations, R a and R b At least one of them is a C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl group, wherein the C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl group is optionally represented by one or more R groups. S replace.
[0248] In some implementations, R a and R b Together with the atoms they are attached to, they form a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group, wherein the C3-C7 cyclic hydrocarbon group or the 3- to 7-membered heterocyclic hydrocarbon group is optionally surrounded by one or more R S replace.
[0249] In some implementations, R a and R b Together with the atoms they are attached to, they form C3-C7 cyclic hydrocarbon groups or 3- to 7-membered heterocyclic hydrocarbon groups.
[0250] In some implementations, R a and R b Together with the atoms they are attached to, they form C3-C7 cyclic hydrocarbon groups or 3- to 7-membered heterocyclic hydrocarbon groups, wherein the C3-C7 cyclic hydrocarbon groups or 3- to 7-membered heterocyclic hydrocarbon groups are affected by one or more R... S replace.
[0251] In some implementations, R a and R b Together with the atoms they are attached to, they form a group optionally bounded by one or more R atoms. S Substituted C3-C7 cyclic hydrocarbon groups.
[0252] In some implementations, R a and R b Together with the atoms they are attached to, they form C3-C7 cyclic hydrocarbon groups.
[0253] In some implementations, R aand R b Together with the atoms they are attached to, they form a group consisting of one or more R atoms. S Substituted C3-C7 cyclic hydrocarbon groups.
[0254] In some implementations, R a and R b Together with the atoms they are attached to, they form a group optionally bounded by one or more R atoms. S Substituted cyclopropyl group.
[0255] In some implementations, R a and R b Together with the atoms they are attached to, they form cyclopropyl groups.
[0256] In some implementations, R a and R b Together with the atoms they are attached to, they form a group consisting of one or more R atoms. S Substituted cyclopropyl group.
[0257] In some implementations, R a and R b Together with the atoms they are attached to, they form a group optionally bounded by one or more R atoms. S Substituted 3- to 7-membered heterocyclic hydrocarbon groups.
[0258] In some implementations, R a and R b Together with the atoms they are attached to, they form 3- to 7-membered heterocyclic hydrocarbon groups.
[0259] In some implementations, R a and R b Together with the atoms they are attached to, they form a group consisting of one or more R atoms. S Substituted 3- to 7-membered heterocyclic hydrocarbon groups.
[0260] In some implementations, at least one R S It is a halogen, -CN, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C1-C6 haloalkyl.
[0261] In some implementations, at least one R S Is it halogen or -CN? In some implementations, at least one R S It is -OH or -O (C1-C6 alkyl).
[0262] In some implementations, at least one R SIt is -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0263] In some implementations, at least one R S It is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C1-C6 haloalkyl.
[0264] Variables Z and R Z In some implementations, Z is -O- or -NR. Z -; where R Z It is an H or C1-C6 alkyl group; In some implementations, Z is -O-. In some implementations, Z is -NR. Z - In some embodiments, Z is -NH-. In some embodiments, Z is -N(C1-C6 alkyl)-. In some embodiments, R Z It is H. In some implementations, R Z It is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl).
[0265] variable R 1 and R 1S In some embodiments, R1 is -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon, -NH-(C3-C 10 -NH-(3- to 7-membered heterocyclic hydrocarbon group) or -NH-(3- to 7-membered heterocyclic hydrocarbon group), wherein -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon group, -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace.
[0266] In some embodiments, R1 is -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon, -NH-(C3-C 10 -NH-(3- to 7-membered heterocyclic hydrocarbon group) or -NH-(3- to 7-membered heterocyclic hydrocarbon group), wherein -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon group, -NH-(C3-C 10The cyclic hydrocarbon group or -NH- (3- to 7-membered heterocyclic hydrocarbon group) is optionally substituted with one or more halogens, -CN, -OH or C1-C6 alkoxy groups.
[0267] In some implementations, R1 is -OH.
[0268] In some embodiments, R1 is -NH2, -NH(C1-C6 alkyl)2, or -N(C1-C6 alkyl)2, wherein the -NH(C1-C6 alkyl)2 or -N(C1-C6 alkyl)2 is optionally replaced by one or more R 1S replace.
[0269] In some implementations, R1 is -NH2.
[0270] In some implementations, R1 is optionally defined by one or more R 1S Substituted -NH (C1-C6 alkyl).
[0271] In some implementations, R1 is optionally defined by one or more R 1S Substituted -N(C1-C6 alkyl)2.
[0272] In some embodiments, R1 is -SH, -S (C1-C6 alkyl) or -S (C6-C6 alkyl). 10 aryl), wherein the -S(C1-C6 alkyl) or -S(C6-C 10 Aryl) optionally by one or more R 1S replace.
[0273] In some implementations, R1 is -SH.
[0274] In some embodiments, R1 is -S (C1-C6 alkyl) or -S (C6-C6 alkyl) 10 aryl), wherein the -S(C1-C6 alkyl) or -S(C6-C 10 Aryl) optionally by one or more R 1S replace.
[0275] In some implementations, R1 is optionally defined by one or more R 1S Substituted -S (C1-C6 alkyl).
[0276] In some embodiments, R1 is -S (C1-C6 alkyl).
[0277] In some implementations, R1 is controlled by one or more R... 1S Substituted -S (C1-C6 alkyl).
[0278] In some implementations, R1 is optionally defined by one or more R 1SReplacement -S(C6-C) 10 Aryl).
[0279] In some implementations, R1 is -S(C6-C 10 Aryl).
[0280] In some implementations, R1 is controlled by one or more R... 1S Replacement -S(C6-C) 10 Aryl).
[0281] In some embodiments, R1 is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon or 3- to 7-membered heterocyclic hydrocarbon, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon or 3- to 7-membered heterocyclic hydrocarbon, optionally bounded by one or more R 1S replace.
[0282] In some implementations, R1 is optionally defined by one or more R 1S Substituted C1-C6 alkyl groups (e.g., methyl, ethyl, or propyl).
[0283] In some embodiments, R1 is a C1-C6 alkyl group (e.g., methyl, ethyl, or propyl).
[0284] In some implementations, R1 is a methyl group.
[0285] In some implementations, R1 is an ethyl group.
[0286] In some implementations, R1 is propyl.
[0287] In some implementations, R1 is controlled by one or more R... 1S Substituted C1-C6 alkyl groups (e.g., methyl, ethyl, or propyl).
[0288] In some implementations, R1 is controlled by one or more R... 1S Substituted methyl group.
[0289] In some implementations, R1 is controlled by one or more R... 1S Substituted ethyl group.
[0290] In some implementations, R1 is controlled by one or more R... 1S Substituted propyl.
[0291] In some implementations, R1 is optionally defined by one or more R 1S Substituted C2-C6 alkenyl groups.
[0292] In some implementations, R1 is optionally defined by one or more R 1S Substituted C2-C6 ynyl group.
[0293] In some implementations, R1 is optionally defined by one or more R 1S Substituted C1-C6 haloalkyl groups.
[0294] In some implementations, R1 is optionally defined by one or more R 1S Substituted C1-C6 alkoxy groups.
[0295] In some implementations, R1 is optionally defined by one or more R 1S Replacement C6-C 10 Aryl.
[0296] In some implementations, R1 is optionally defined by one or more R 1S Substituted 5- to 10-membered heteroaryl groups.
[0297] In some implementations, R1 is optionally defined by one or more R 1S Substituted C3-C7 cyclic hydrocarbon groups.
[0298] In some implementations, R1 is optionally defined by one or more R 1S Substituted C3-C7 cyclic hydrocarbon groups.
[0299] In some implementations, R1 is optionally defined by one or more R 1S Substituted cyclopropyl group.
[0300] In some embodiments, R1 is a cyclopropyl group optionally substituted with one or more halogens.
[0301] In some embodiments, R1 is a cyclopropyl group optionally substituted with one or more F groups.
[0302] In some implementations, R1 is optionally defined by one or more R 1S Substituted 3- to 7-membered heterocyclic hydrocarbon groups.
[0303] In some implementations, R1 is -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -O-(3- to 7-membered heterocyclic hydrocarbon group), wherein the -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C10 (cyclic hydrocarbon group) or -O-(3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace.
[0304] In some implementations, R1 is optionally defined by one or more R 1S Replacement -O-(C6-C) 10 Aryl).
[0305] In some implementations, R1 is optionally defined by one or more R 1S Substituted -O-(5- to 10-membered heteroaryl).
[0306] In some implementations, R1 is optionally defined by one or more R 1S Replacement -O-(C3-C) 10 (cyclic hydrocarbon group).
[0307] In some implementations, R1 is optionally defined by one or more R 1S Substituted -O-(3- to 7-membered heterocyclic hydrocarbon groups).
[0308] In some implementations, R1 is -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 (C6-C) or -NH- (3- to 7-membered heterocyclic hydrocarbon group), wherein the NH- (C6-C) 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace.
[0309] In some implementations, R1 is optionally defined by one or more R 1S Substituted -NH-(C6-C 10 Aryl).
[0310] In some implementations, R1 is optionally defined by one or more R 1S Substituted -NH-(5- to 10-membered heteroaryl).
[0311] In some implementations, R1 is optionally defined by one or more R 1S Substituted -NH-(C3-C 10 (cyclic hydrocarbon group).
[0312] In some implementations, R1 is optionally defined by one or more R 1S Substituted -NH-(3- to 7-membered heterocyclic hydrocarbon groups).
[0313] In some implementations, at least one R 1S It is a halogen (e.g., F), -CN, -OH, or C1-C6 alkoxy group.
[0314] In some implementations, at least one R 1S It is oxygenation.
[0315] In some implementations, at least one R 1S It is a halogen (e.g., F, Cl or Br).
[0316] In some implementations, at least one R 1S It is F. In some implementations, at least one R 1S It is Cl. In some implementations, at least one R 1S It is Br.
[0317] In some implementations, at least one R 1S Yes -CN. In some implementations, at least one R 1S It is -OH.
[0318] In some implementations, at least one R 1S It is -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0319] In some implementations, at least one R 1S It is -S (C1-C6 alkyl). In some embodiments, at least one R 1S It is -SO2 (C1-C6 alkyl).
[0320] In some implementations, at least one R 1S It is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 alkoxy group.
[0321] In some implementations, at least one R 1S It is a C1-C6 alkyl group. In some embodiments, at least one R 1S It is a C2-C6 alkenyl group. In some embodiments, at least one R 1S It is a C2-C6 acetylene group.
[0322] In some implementations, at least one R 1S It is a C1-C6 alkoxy group.
[0323] In some implementations, at least one R 1S It is a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group.
[0324] In some implementations, at least one R 1SIt is a C3-C7 cyclic hydrocarbon group.
[0325] In some implementations, at least one R 1S It is a 3- to 7-membered heterocyclic hydrocarbon group.
[0326] variable Ar 1 and R A1 In some implementations, Ar1 is optionally controlled by one or more R A1 Replacement C6-C 10 Aryl.
[0327] In some implementations, Ar1 is C6-C 10 Aryl.
[0328] In some implementations, Ar1 is controlled by one or more R A1 Replacement C6-C 10 Aryl.
[0329] In some implementations, Ar1 is optionally controlled by one or more R A1 Substituted phenyl groups.
[0330] In some implementations, Ar1 is .
[0331] In some implementations, Ar1 is .
[0332] In some implementations, Ar1 is phenyl.
[0333] In some implementations, Ar1 is controlled by one or more R A1 Substituted phenyl groups.
[0334] In some implementations, Ar1 is optionally controlled by one or more R A1 Substituted 5- to 10-membered heteroaryl groups.
[0335] In some implementations, Ar1 is a 5- to 10-membered heteroaryl group.
[0336] In some implementations, Ar1 is controlled by one or more R A1 Substituted 5- to 10-membered heteroaryl groups.
[0337] In some implementations, Ar1 is optionally controlled by one or more R A1 Substituted pyridinyl or thiazolyl groups.
[0338] In some implementations, Ar1 is pyridyl or thiazolyl.
[0339] In some implementations, Ar1 is controlled by one or more R A1 Substituted pyridinyl or thiazolyl groups.
[0340] In some implementations, Ar1 is optionally controlled by one or more R A1 Substituted pyridinyl group.
[0341] In some implementations, Ar1 is .
[0342] In some implementations, Ar1 is pyridyl.
[0343] In some implementations, Ar1 is controlled by one or more R A1 Substituted pyridinyl group.
[0344] In some implementations, Ar1 is optionally controlled by one or more R A1 Substituted thiazole group.
[0345] In some implementations, Ar1 is a thiazolyl group.
[0346] In some implementations, Ar1 is controlled by one or more R A1 Substituted thiazole group.
[0347] In some implementations, at least one R A1 It is Ar2.
[0348] In some implementations, an R A1 It is Ar2.
[0349] In some implementations, at least one R A1 It is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 replace.
[0350] In some implementations, at least one R A1 It is optionally controlled by one or more R A2 Replacement C6-C 10 Aryl.
[0351] In some implementations, at least one R A1 It is C6-C 10 Aryl.
[0352] In some implementations, at least one R A1 It is by one or more R A2 Replacement C6-C 10 Aryl.
[0353] In some implementations, at least one R A1 It is optionally controlled by one or more R A2 Substituted phenyl groups.
[0354] In some implementations, at least one R A1 It is phenyl.
[0355] In some implementations, at least one R A1 It is by one or more R A2 Substituted phenyl groups.
[0356] In some implementations, at least one R A1 It is optionally controlled by one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0357] In some implementations, at least one R A1 It is a 5- to 10-membered heteroaryl group.
[0358] In some implementations, at least one R A1 It is by one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0359] In some implementations, at least one R A1 It is optionally controlled by one or more R A2 Substituted pyridinyl or thiazolyl groups.
[0360] In some implementations, at least one R A1 It is either pyridinyl or thiazolyl.
[0361] In some implementations, at least one R A1 It is by one or more R A2 Substituted pyridinyl or thiazolyl groups.
[0362] In some implementations, at least one R A1 It is optionally controlled by one or more R A2 Substituted pyridinyl group.
[0363] In some implementations, at least one R A1 It is pyridyl.
[0364] In some implementations, at least one R A1 It is by one or more R A2 Substituted pyridinyl group.
[0365] In some implementations, at least one R A1 It is optionally controlled by one or more R A2 Substituted thiazole group.
[0366] In some implementations, at least one R A1 It is a thiazole group.
[0367] In some implementations, at least one R A1 It is by one or more R A2 Substituted thiazole group.
[0368] In some implementations, at least one R A1 It is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0369] In some implementations, at least one R A1 It is a halogen (e.g., F, Cl or Br).
[0370] In some implementations, at least one R A1 It is F. In some implementations, at least one R A1 It is Cl. In some implementations, at least one R A1 It is Br.
[0371] In some implementations, at least one R A1 Yes -CN. In some implementations, at least one R A1 It is -OH.
[0372] In some implementations, at least one R A1 It is -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0373] In some implementations, at least one R A1 It is a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, or C2-C6 alkynyl.
[0374] In some implementations, at least one R A1 It is a C1-C6 alkyl group.
[0375] In some implementations, at least one R A1 It is a C1-C6 haloalkyl group (e.g., -CH2F, -CHF2, or -CF3).
[0376] In some implementations, at least one R A1 It is a C1-C6 alkoxy group.
[0377] In some implementations, at least one R A1 It is a C1-C6 haloalkoxy group (e.g., -OCH2F, -OCHF2, or -OCF3).
[0378] In some implementations, at least one R A1 It is a C2-C6 alkenyl group. In some embodiments, at least one R A1 It is a C2-C6 acetylene group.
[0379] variable T In some implementations, T is absent.
[0380] In some implementations, T is Ar2.
[0381] In some implementations, T is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 replace.
[0382] In some implementations, T is optionally represented by one or more R A2 Replacement C6-C 10 Aryl.
[0383] In some implementations, T is .
[0384] In some implementations, T is C6-C 10 Aryl.
[0385] In some implementations, T is controlled by one or more R A2 Replacement C6-C 10 Aryl.
[0386] In some implementations, T is optionally represented by one or more R A2 Substituted phenyl groups.
[0387] In some implementations, T is phenyl.
[0388] In some implementations, T is controlled by one or more R A2 Substituted phenyl groups.
[0389] In some implementations, T is optionally represented by one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0390] In some implementations, T is a 5- to 10-membered heteroaryl group.
[0391] In some implementations, T is controlled by one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0392] In some implementations, T is optionally represented by one or more R A2 Substituted pyridinyl or thiazolyl groups.
[0393] In some implementations, T is pyridinyl or thiazolyl.
[0394] In some implementations, T is controlled by one or more R A2 Substituted pyridinyl or thiazolyl groups.
[0395] In some implementations, T is optionally represented by one or more R A2 Substituted pyridinyl group.
[0396] In some implementations, T is pyridyl.
[0397] In some implementations, T is controlled by one or more R A2 Substituted pyridinyl group.
[0398] In some implementations, T is optionally represented by one or more R A2 Substituted thiazole group.
[0399] In some implementations, T is a thiazolyl group.
[0400] In some implementations, T is controlled by one or more R A2 Substituted thiazole group.
[0401] variable Ar 1 、R A1 Exemplary implementations of T In some implementations, at least one R A1 It is Ar2, and T does not exist.
[0402] In some implementations, at least one R A1 It is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 Replace, and T does not exist.
[0403] In some implementations, at least one R A1 It is optionally controlled by one or more R A2 Replacement C6-C 10 Aryl group, and T does not exist.
[0404] In some implementations, at least one R A1 It is optionally controlled by one or more R A2 The substituted phenyl group, and T is absent.
[0405] In some implementations, at least one R A1 It is optionally controlled by one or more R A2 The substituted 5- to 10-membered heteroaryl groups are present, and T is absent.
[0406] In some implementations, at least one R A1 It is optionally controlled by one or more R A2 The substituted pyridinyl or thiazolyl group is present, and T is absent.
[0407] In some implementations, Ar1 is And T does not exist.
[0408] In some implementations, each R A1 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; and T is Ar2.
[0409] In some implementations, Ar1 is optionally controlled by one or more R A1 Replacement C6-C 10 Aryl, and T is Ar2.
[0410] In some implementations, Ar1 is optionally controlled by one or more R A1 The substituted 5- to 10-membered heteroaryl group, and T is Ar2.
[0411] In some implementations, Ar1 is And T is Ar2.
[0412] In some implementations, Ar1 is And T is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 replace.
[0413] In some implementations, Ar1 is And T is optionally defined by one or more R A2 Replacement C6-C 10 Aryl.
[0414] In some implementations, Ar1 is And T is optionally defined by one or more R A2 Substituted phenyl groups.
[0415] In some implementations, Ar1 is And T is .
[0416] In some implementations, Ar1 is And T is optionally defined by one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0417] In some implementations, Ar1 is And T is optionally defined by one or more R A2 Substituted pyridinyl or thiazolyl groups.
[0418] In some implementations, Ar1 is And T is Ar2.
[0419] In some implementations, each R A1 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; and T is Ar2.
[0420] In some implementations, each R A1 Independently, it is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; and T is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 replace.
[0421] In some implementations, each R A1 Independently, it is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, or C2-C6 alkynyl; and T is optionally separated by one or more R A2 Replacement C6-C 10 Aryl.
[0422] In some implementations, each RA1 Independently, it is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, or C2-C6 alkynyl; and T is optionally separated by one or more R A2 Substituted phenyl groups.
[0423] In some implementations, each R A1 Independently, it is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, or C2-C6 alkynyl; and T is .
[0424] In some implementations, each R A1 Independently, it is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, or C2-C6 alkynyl; and T is optionally separated by one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0425] In some implementations, each R A1 Independently, it is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, or C2-C6 alkynyl; and T is optionally separated by one or more R A2 Substituted pyridinyl or thiazolyl groups.
[0426] variable Ar 2 and R A2 In some implementations, at least one Ar2 is C6-C. 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 replace.
[0427] In some implementations, at least one Ar2 is optionally mixed with one or more R A2 Replacement C6-C 10 Aryl.
[0428] In some implementations, at least one Ar2 is C6-C. 10 Aryl.
[0429] In some implementations, at least one Ar2 is subjected to one or more R A2 Replacement C6-C 10 Aryl.
[0430] In some implementations, at least one Ar2 is optionally mixed with one or more R A2 Substituted phenyl groups.
[0431] In some embodiments, at least one Ar2 is a phenyl group.
[0432] In some implementations, at least one Ar2 is subjected to one or more R A2 Substituted phenyl groups.
[0433] In some implementations, at least one Ar2 is optionally mixed with one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0434] In some embodiments, at least one Ar2 is a 5- to 10-membered heteroaryl group.
[0435] In some implementations, at least one Ar2 is subjected to one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0436] In some implementations, at least one Ar2 is optionally mixed with one or more R A2 Substituted pyridinyl or thiazolyl groups.
[0437] In some embodiments, at least one Ar2 is pyridyl or thiazolyl.
[0438] In some implementations, at least one Ar2 is subjected to one or more R A2 Substituted pyridinyl or thiazolyl groups.
[0439] In some implementations, at least one Ar2 is optionally mixed with one or more R A2 Substituted pyridinyl group.
[0440] In some implementations, at least one Ar2 is pyridyl.
[0441] In some implementations, at least one Ar2 is subjected to one or more R A2 Substituted pyridinyl group.
[0442] In some implementations, at least one Ar2 is optionally mixed with one or more R A2 Substituted thiazole group.
[0443] In some implementations, at least one Ar2 group is a thiazolyl group.
[0444] In some implementations, at least one Ar2 is subjected to one or more R A2 Substituted thiazole group.
[0445] In some implementations, at least one R A2 It is a halogen (e.g., F, Cl or Br).
[0446] In some implementations, at least one R A2 It is F. In some implementations, at least one R A2 It is Cl. In some implementations, at least one R A2 It is Br.
[0447] In some implementations, at least one R A2 Yes -CN. In some implementations, at least one R A2 It is -OH.
[0448] In some implementations, at least one R A2 It is -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0449] In some implementations, at least one R A2 It is a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, or C2-C6 alkynyl.
[0450] In some implementations, at least one R A2 It is a C1-C6 alkyl group.
[0451] In some implementations, at least one R A2 It is a C1-C6 alkoxy group.
[0452] In some implementations, at least one R A2 It is a C1-C6 haloalkyl group (e.g., -CH2F, -CHF2, or -CF3).
[0453] In some implementations, at least one R A2 It is a C2-C6 alkenyl group. In some embodiments, at least one R A2 It is a C2-C6 acetylene group.
[0454] Exemplary embodiments of the compound In some embodiments, the compound has formula (I'-a) or (I'-b): (I'-a)or (I'-b); Or its pharmaceutically acceptable salt.
[0455] In some embodiments, the compound has the formula (IA'), (IA'-a), or (IA'-b): (IA'), (IA'-a)or (IA'-b); Or its pharmaceutically acceptable salt.
[0456] In some embodiments, the compound has the formula (IB'), (IB'-a), or (IB'-b): (IB'), (IB'-a) or (IB'-b); Or its pharmaceutically acceptable salt.
[0457] In some embodiments, the compound has the formula (II'), (II'-a), or (II'-b): (II'), (II'-a) or (II'-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4.
[0458] In some embodiments, the compound has the formula (IIA'), (IIA'-a), or (IIA'-b): (IIA'), (IIA'-a) or (IIA'-b); Or its pharmaceutically acceptable salt.
[0459] In some embodiments, the compound has the formula (IIB'), (IIB'-a), or (IIB'-b): (IIB'), (IIB'-a) or (IIB'-b); Or its pharmaceutically acceptable salt.
[0460] In some embodiments, the compound has the formula (IIIA'), (IIIA'-a), or (IIIA'-b): (IIIA'), (IIIA'-a) or (IIIA'-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0461] In some embodiments, the compound has the formula (IIIB'), (IIIB'-a), or (IIIB'-b): (IIIB'), (IIIB'-a) or (IIIB'-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 3; and n2 is an integer in the range of 0 to 5.
[0462] In some embodiments, the compound has the formula (IVA'), (IVA'-a), or (IVA'-b): (IVA'), (IVA'-a) or (IVA'-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0463] In some embodiments, the compound has the formula (VA'), (VA'-a), or (VA'-b): (VA'), (VA'-a) or (VA'-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0464] In some embodiments, the compound has formula (Ia) or (Ib): (Ia)or (Ib); Or its pharmaceutically acceptable salt.
[0465] In some embodiments, the compound has the formula (IA), (IA-a), or (IA-b): (IA), (IA-a) or (IA-b); Or its pharmaceutically acceptable salt.
[0466] In some embodiments, the compound has the formula (IB), (IB-a), or (IB-b): (IB), (IB-a) or (IB-b); Or its pharmaceutically acceptable salt.
[0467] In some embodiments, the compound has formula (II), (II-a), or (II-b): (II), (II-a) or (II-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4.
[0468] In some embodiments, the compound has the formula (IIA), (IIA-a), or (IIA-b): (IIA), (IIA-a) or (IIA-b); Or its pharmaceutically acceptable salt.
[0469] In some embodiments, the compound has the formula (IIB), (IIB-a), or (IIB-b): (IIB), (IIB-a) or (IIB-b); Or its pharmaceutically acceptable salt.
[0470] In some embodiments, the compound has the formula (IIIA), (IIIA-a), or (IIIA-b): (IIIA), (IIIA-a) or (IIIA-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0471] In some embodiments, the compound has the formula (IIIB), (IIIB-a), or (IIIB-b): (IIIB), (IIIB-a) or (IIIB-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 3; and n2 is an integer in the range of 0 to 5.
[0472] In some embodiments, the compound has the formula (IVA), (IVA-a), or (IVA-b): (IVA), (IVA-a) or (IVA-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0473] In some embodiments, the compound has the formula (VA), (VA-a), or (VA-b): (VA), (VA-a) or (VA-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0474] In some embodiments, the compound has the structural formula described herein or a pharmaceutically acceptable salt thereof, wherein: R1 is -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon, -NH-(C3-C 10 -NH-(3- to 7-membered heterocyclic hydrocarbon group), wherein -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon group, -NH-(C3 ... -NH-(C1-C6 alkyl)2, 5- to 10-membered heteroaryl, -NH-(C1-C6 alkyl)2, 5- to 10-membered heteroaryl, -NH-(C1-C6 alkyl)2, 5- 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S Substitution and C1-C6 alkyl groups are formed by one or more R 1S replace; Each R 1S It is independently a halogen or a C1-C6 alkyl group; Each R A1 It is a halogen on its own; Each R A2 It is a halogen on its own; n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0475] In some embodiments, the compound is selected from the compounds described in Table A1 and their pharmaceutically acceptable salts.
[0476] In some embodiments, the compound is selected from compound numbers A1-6, A1-6, A1-10, A1-15, A1-42, A1-58, A1-59, A1-60, A1-61, A1-63 to A1-102 and their pharmaceutically acceptable salts.
[0477] In some embodiments, the compound is selected from the compounds described in Table A2 and their pharmaceutically acceptable salts.
[0478] In some embodiments, the compound is selected from the compounds described in Table B1 and their pharmaceutically acceptable salts.
[0479] In some embodiments, the compound is selected from the compounds described in Table B2 and their pharmaceutically acceptable salts.
[0480] Table A1 Table A2 Table B1 Table B2 In some embodiments, the compound is a pharmaceutically acceptable salt of any of the compounds described in Tables A1, A2, B1, and B2.
[0481] In some respects, this disclosure provides compounds that are isotopic derivatives (e.g., isotopically labeled compounds) of any of the formulas disclosed herein.
[0482] In some embodiments, the compound is an isotopic derivative of any of the compounds described in Tables A1, A2, B1, and B2, as well as its prodrug and pharmaceutically acceptable salt.
[0483] In some embodiments, the compound is an isotopic derivative of any of the compounds described in Tables A1, A2, B1, and B2, and a pharmaceutically acceptable salt thereof.
[0484] In some embodiments, the compound is an isotopic derivative of a prodrug of any of the compounds described in Tables A1, A2, B1, and B2, or a pharmaceutically acceptable salt thereof.
[0485] In some embodiments, the compound is an isotopic derivative of any of the compounds described in Tables A1, A2, B1, and B2.
[0486] It should be understood that isotope derivatives can be prepared using any of a variety of techniques recognized in the art. For example, isotope derivatives can typically be prepared by replacing non-isotope-labeled reagents with isotope-labeled reagents and by performing the procedures disclosed in the schemes described herein and / or in the examples.
[0487] In some embodiments, the isotope derivative is a deuterium-labeled compound.
[0488] In some embodiments, the isotope derivative is a deuterium-labeled compound of any of the various compounds disclosed herein.
[0489] As used herein, the term "isotope derivative" refers to a derivative of a compound in which one or more atoms are enriched or labeled with an isotope. For example, compared to the corresponding compound of formula (I), an isotope derivative of the compound of formula (I) is isotopically enriched or labeled with one or more isotopes. In some embodiments, the isotope derivative is enriched or labeled with one or more atoms selected from... 2 H, 13 C 14 C 15 N、 18 O、 29 Si、 31 P and 34 S. In some embodiments, the isotope derivative is a deuterium-labeled compound (i.e., deuterium-labeled with respect to one or more atoms). 2 H enrichment). In some embodiments, the compound is 18 An F-labeled compound. In some embodiments, the compound is... 123 I-labeled compounds, 124 I-labeled compounds, 125 I-labeled compounds, 129 I-labeled compounds, 131 I-labeled compounds, 135 I-labeled compounds or any combination thereof. In some embodiments, the compound is... 33 S-labeled compounds, 34 S-labeled compounds, 35 S-labeled compounds, 36 S-labeled compounds or any combination thereof.
[0490] It should be understood that any of a variety of techniques recognized in the art can be used to prepare 18 F, 123 I, 124 I, 125 I, 129 I, 131 I, 135 I, 32 S, 34 S, 35 S and / or 36 S-labeled compounds. For example, by performing the procedures disclosed in the schemes described herein and / or in the examples, by using... 18 F, 123 I, 124 I, 125 I, 129 I, 131 I,135 I, 3 S, 34 S, 35 S and / or 36 Deuterium-labeled compounds can usually be prepared by using S-labeled reagents instead of non-isotope-labeled reagents.
[0491] Containing the aforementioned 18 F, 123 I, 124 I, 125 I, 129 I, 131 I, 135 I, 32 S, 34 S, 35 S and 36 One or more of the compounds of the present invention, or their pharmaceutically acceptable salts or solvates, containing S atoms are within the scope of the present invention. Furthermore, isotopes (e.g., 18 F, 123 I, 124 I, 125 I, 129 I, 131 I, 135 I, 3 S, 34 S, 35 S and / or 36 S) replacement may offer certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dose requirements.
[0492] To avoid confusion, it should be understood that when a group is defined in this specification as “described herein”, the group includes the first and broadest definition and each and all of the specific definitions within that group.
[0493] The various functional groups and substituents of compounds of formula (I) are typically chosen such that the molecular weight of the compound does not exceed 1000 Daltons. More typically, the molecular weight of the compound will be less than 900, for example less than 800, or less than 750, or less than 700, or less than 650 Daltons. More conveniently, the molecular weight is less than 600, and, for example, 550 Daltons or less.
[0494] Suitable pharmaceutically acceptable salts of the compounds disclosed herein are, for example, acid addition salts of the compounds of this disclosure that are sufficiently basic, such as acid addition salts formed with, for example, inorganic or organic acids (e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, formic acid, citric acid, methanesulfonic acid, or maleic acid). Furthermore, suitable pharmaceutically acceptable salts of the compounds of this disclosure that are sufficiently acidic are alkali metal salts, such as sodium or potassium salts, alkaline earth metal salts, such as calcium or magnesium salts, ammonium salts, or salts with organic bases that provide pharmaceutically acceptable cations, such as salts with methylamine, dimethylamine, diethylamine, trimethylamine, piperidine, morpholine, or tri-(2-hydroxyethyl)amine.
[0495] It should be understood that any compound of any of the formulas disclosed herein and any pharmaceutically acceptable salt thereof comprises stereoisomers, mixtures of stereoisomers, and polymorphs of all isomeric forms of the compound.
[0496] It should be understood that while the compounds disclosed herein may exist in a particular configuration, such a particular configuration should not be construed as limiting the disclosure to one or another isomer, tautomer, positional isomer, or stereoisomer, nor does it exclude mixtures of isomers, tautomers, positional isomers, or stereoisomers. In some embodiments, the presentation of compounds in a particular configuration herein is intended to cover and refer to each of the available isomers, tautomers, positional isomers, and stereoisomers of the compound, or any mixture thereof; although the presentation is further intended to refer to a specific configuration of the compound. For example, when presenting having When referring to compounds that are part of a compound, the presentation may be intended to cover and refer to compounds having... , , or The present invention may refer to a compound or any mixture thereof. Furthermore, the presentation may be intended to indicate having A compound with a specific configuration.
[0497] It should be understood that while compounds disclosed herein may be presented without a specified configuration (e.g., without a specified stereochemistry), such presentation is intended to cover all available isomers, tautomers, positional isomers, and stereoisomers of the compounds. In some embodiments, the presentation of compounds herein without a specified configuration is intended to refer to each or any mixture of the available isomers, tautomers, positional isomers, and stereoisomers of the compounds. For example, when presenting compounds having… When referring to compounds that are part of a compound, the presentation may be intended to cover and refer to compounds having... , , or The presenting may refer to a compound having the portion thereof or any mixture thereof. Furthermore, the presentation may be intended to refer to a mixture of cis isomers having the portion (e.g., and Compounds that are mixtures of parts thereof. For example, when presenting with... When referring to a portion of a compound, the presentation may be intended to indicate having , Compounds thereof or mixtures thereof.
[0498] As used in this article, "isomerism" refers to compounds with the same molecular formula but different atomic bonding sequences or spatial arrangements. Isomers with different spatial arrangements of atoms are called "stereoisomers." Stereoisomers that are not mirror images of each other are called "diastereomers," while stereoisomers that are non-overlapping mirror images of each other are called "enantiomers" or sometimes optical isomers. A mixture containing equal amounts of enantiomers with opposite chirality is called a "racemic mixture."
[0499] As used in this article, the term "chiral center" refers to a carbon atom bonded to four different substituents.
[0500] As used herein, the term "chiral isomer" refers to a compound having at least one chiral center. Compounds having more than one chiral center may exist as individual diastereomers or as mixtures of diastereomers, referred to as "diastereomer mixtures." When a chiral center is present, the stereoisomer can be characterized by the absolute configuration (R or S) of that chiral center. The absolute configuration indicates the spatial arrangement of substituents attached to the chiral center. Substituents attached to the chiral center under consideration are ordered according to the order rules of Cahn, Ingold, and Prelog (Cahn et al.). Angew . Chem . Inter . Edit . 1966, 5, 385; errata 511; Cahn et al., Angew . Chem . 1966, 78,413; Cahn and Ingold, J . Chem . Soc . 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J . Chem . Educ . 1964, 41, 116).
[0501] As used herein, the term "geometric isomer" refers to diastereomers that exist due to hindered rotation around a double bond or a cyclic alkyl linker (e.g., 1,3-cyclobutyl). According to the Cahn-Ingold-Prelog rule, these configurations are distinguished by the prefixes cis and trans, or Z and E, indicating that the group is located on the same or opposite sides of the double bond in the molecule.
[0502] It should be understood that the compounds of this disclosure may be described as different chiral or geometric isomers. It should also be understood that when a compound has chiral or geometric isomers, all isomers are intended to be included within the scope of this disclosure, and the naming of the compound does not exclude any isomer. It should be understood that not all isomers may have the same level of activity.
[0503] It should be understood that the structures and other compounds discussed in this disclosure include all their transisomers. It should also be understood that not all transisomers possess the same level of activity.
[0504] The term "trans-isomer" as used in this article refers to a class of stereoisomers in which the atoms of the two isomers are arranged differently in space. The existence of trans-isomers is attributed to restricted rotation caused by the impeded rotation of the large group around the central bond. Such trans-isomers usually exist as mixtures, but due to recent advances in chromatographic techniques, mixtures of two trans-isomers can now be separated under certain conditions.
[0505] As used in this article, a "tautomer" is one of two or more structural isomers existing in equilibrium, and which readily transforms from one isomer to another. This transformation results in the migration of hydrogen atoms, accompanied by the conversion of adjacent conjugated double bonds. Tautomers exist as a mixture of tautomer combinations in solution. In solutions where tautomerization is possible, a chemical equilibrium of tautomers will be reached. The exact ratio of tautomers depends on several factors, including temperature, solvent, and pH. The concept of tautomers that can interconvert through tautomerization is called tautomerism. Of the various possible types of tautomerism, two are commonly observed. In keto-enol tautomerism, simultaneous shifts of electrons and hydrogen atoms occur. Ring-chain tautomerism arises because the aldehyde group (-CHO) in a sugar molecule reacts with one of the hydroxyl groups (-OH) in the same molecule to produce a cyclic (ring-like) form, as exhibited by glucose.
[0506] It should be understood that the compounds of this disclosure may be described as different tautomers. It should also be understood that when a compound has tautomer forms, all tautomer forms are intended to be included within the scope of this disclosure, and the naming of the compound does not exclude any tautomer form. It should be understood that some tautomers may have higher activity levels than others.
[0507] Compounds with the same molecular formula but different atomic bonding properties or sequences, or different spatial arrangements of atoms, are called "isomers." Isomers with different spatial arrangements of atoms are called "stereoisomers." Stereoisomers that are not mirror images of each other are called "diastereomers," and stereoisomers that are non-overlapping mirror images of each other are called "enantiomers." When a compound has an asymmetry center, for example, when it is bonded to four different groups, a pair of enantiomers may exist. Enantiomers can be characterized by the absolute configuration of their asymmetry center and described by the R- and S-ordering rules of Cahn and Prelog, or by rotating the molecular polarization plane and specifying them as dextrorotatory or levorotatory (i.e., (+) or (-)-isomers, respectively). Chiral compounds can exist as single enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is called a "racemic mixture."
[0508] The compounds of this disclosure may have one or more asymmetric centers; therefore, such compounds can be prepared as individual (R)- or (S)- stereoisomers or mixtures thereof. Unless otherwise indicated, the description or naming of a particular compound in the specification and claims is intended to include its single enantiomer and racemic or other mixtures. Methods for determining stereochemistry and isolating stereoisomers are well known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry," 4th edition, J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active starting materials or by resolving the racemic form. Some compounds of this disclosure may have geometric isomer centers (E- and Z-isomers). It should be understood that this disclosure covers all optical diastereomers and geometric isomers and mixtures thereof having inflammasome inhibitory activity.
[0509] This disclosure also includes compounds as defined herein that contain one or more isotope substitutions.
[0510] It should be understood that any compound of any kind described herein includes the compound itself, as well as, where applicable, their salts and their solvates. For example, salts can be formed between anion and a positively charged group (e.g., amino group) on the substituted compound disclosed herein. Suitable anions include chloride, bromide, iodide, sulfate, hydrogen sulfate, aminosulfonate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, toluenesulfonate, salicylate, lactate, naphthalenesulfonate, and acetate (e.g., trifluoroacetate).
[0511] As used herein, the term "pharmaceutically acceptable anion" refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts can also be formed between a cation and a negatively charged group (e.g., a carboxyl group) on the substituted compounds disclosed herein. Suitable cations include sodium, potassium, magnesium, calcium, and ammonium cations such as tetramethylammonium or diethylamine ions. The substituted compounds disclosed herein also include those salts containing a quaternary nitrogen atom.
[0512] It should be understood that the compounds of this disclosure, such as salts of the compounds, may exist in hydrated or non-hydrated (anhydrous) form or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates, dihydrates, etc. Non-limiting examples of solvates include ethanol solvates, acetone solvates, etc.
[0513] As used herein, the term "solvent" refers to a solvation form containing stoichiometric or non-stoichiometric amounts of solvent. Some compounds tend to trap a fixed molar ratio of solvent molecules in their crystalline solid state, thus forming a solvate. If the solvent is water, the solvate formed is a hydrate; if the solvent is an alcohol, the solvate formed is an alcohol. A hydrate is formed by the combination of one or more water molecules with a substance molecule, wherein the water retains its molecular state as H₂O.
[0514] As used herein, the term "analogue" refers to a compound that is structurally similar to another but has a slightly different composition (e.g., by substitution of an atom with an atom of a different element, or in the presence of a specific functional group, or by the substitution of one functional group by another). Therefore, an analogue is a compound that is functionally similar or equivalent in appearance but differs from the reference compound in structure or origin.
[0515] As used in this article, the term "derivative" refers to compounds that share a common core structure and are substituted by various groups as described herein.
[0516] As used herein, the term "bioisostere" refers to a compound resulting from the exchange of one atom or group of atoms with another substantially similar atom or group of atoms. The aim of bioisostere substitution is to create a new compound with biological properties similar to the parent compound. Bioisostere substitution can be based on physicochemical or topological principles. Examples of carboxylic acid bioisosteres include, but are not limited to, acylsulfonamides, tetrazolium, sulfonates, and phosphonates. See, for example, Patani and LaVoie. Chem . Rev 96, 3147-3176, 1996.
[0517] It should also be understood that certain compounds of any of the formulas disclosed herein may exist in both solvated and unsolvated forms, such as, for example, hydrated forms. Suitable pharmaceutically acceptable solvates are, for example, hydrates such as hemihydrates, monohydrates, dihydrates, or trihydrates. It should be understood that this disclosure includes all such solvated forms having inflammasome-inhibiting activity.
[0518] It should also be understood that certain compounds of any of the formulas disclosed herein may exhibit polymorphism, and this disclosure includes all such forms or mixtures thereof that have inflammasome-inhibiting activity. It is generally known that crystalline materials can be analyzed using conventional techniques such as X-ray powder diffraction, differential scanning calorimetry, thermogravimetric analysis, diffuse reflectance infrared Fourier transform (DRIFT) spectroscopy, near-infrared (NIR) spectroscopy, and solution and / or solid-state nuclear magnetic resonance spectroscopy. The water content of such crystalline materials can be determined by Karl Fischer analysis.
[0519] Compounds of any formula disclosed herein may exist in many different tautomer forms, and references to compounds of formula (I) include all such forms. For the avoidance of confusion, where a compound may exist in one of several tautomer forms and only one is specifically described or shown, all other forms are still included in formula (I). Examples of tautomer forms include ketone-, enol-, and enolide- forms, such as in, for example, the following tautomer pairs: ketone / enol (exemplified below), imine / enamine, amide / imino alcohol, amidine / amidinium, nitroso / oxime, thionone / enthiol, and nitro / acid nitro. Compounds of any of the formulas disclosed herein containing an amine functional group can also form N-oxides. Compounds of formula (I) containing an amine functional group mentioned herein also include N-oxides. In the case of compounds containing several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxides. Specific examples of N-oxides are N-oxides of tertiary amines or nitrogen atoms in nitrogen-containing heterocycles. N-oxides can be formed by treating the corresponding amine with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid), see, for example, Jerry March, Advanced Organic Chemistry, 4th ed., Wiley Interscience, p. More specifically, N-oxides can be prepared by LW Deady's procedure (Syn. Comm. 1977, 7, 509-514), in which an amine compound is reacted with m-chloroperoxybenzoic acid (mCPBA), for example in an inert solvent such as dichloromethane.
[0520] Compounds of any of the formulas disclosed herein can be administered as prodrugs, which decompose in humans or animals to release the compounds of this disclosure. Prodrugs can be used to modify the physical and / or pharmacokinetic properties of the compounds of this disclosure. Prodrugs can be formed when the compounds of this disclosure contain suitable groups or substituents (to which modifying groups may be attached). Examples of prodrugs include derivatives of any of the formulas disclosed herein containing in vivo cleavable alkyl or acyl substituents at the ester or amide group.
[0521] Therefore, this disclosure includes compounds of any of the formulas disclosed herein as defined above, whether obtained by organic synthesis or obtained in humans or animals by cleavage of their prodrugs. Thus, this disclosure includes compounds of any of the formulas disclosed herein produced by organic synthesis, and compounds produced in humans or animals by the metabolism of prodrug compounds, i.e., compounds of any of the formulas disclosed herein can be synthetically produced or metabolically produced compounds.
[0522] A suitable pharmaceutically acceptable prodrug for any of the compounds disclosed herein is one that, based on reasonable medical judgment, is suitable for administration to humans or animals without undesirable pharmacological activity and without inappropriate toxicity. Various forms of prodrugs have been described, for example, in the following documents: a) Methods in Enzymology, Vol. 42, pp. 309–396, eds. K. Widder et al. (Academic Press, 1985); b) Design of Prodrugs, ed. H. Bundgaard (Elsevier, 1985); c) A Textbook of Drug Design and Development, eds. Krogsgaard-Larsen and H. Bundgaard, Chapter 5, “Design and Application of Prodrugs”, H. Bundgaard, pp. 113–191 (1991); d) H. Bundgaard, Advanced Drug Delivery Reviews, 8, 1–38 (1992); e) H. Bundgaard et al., Journal of Pharmaceutical Sciences, 77, 285 (1988); f) N. Kakeya et al., Chem. Pharm. Bull., 32, 692 (1984); g) T. Higuchi and V. Stella, “Pro-Drugs as Novel Delivery Systems”, ACS Symposium Series, Vol. 14; and h) E. Roche (ed.), “Bioreversible Carriers in Drug Design”, Pergamon Press, 1987.
[0523] Suitable pharmaceutically acceptable prodrugs of compounds having a hydroxyl group in any of the formulas disclosed herein are, for example, esters or ethers that are cleavable in vivo. Suitable pharmaceutically acceptable ester-forming groups of compounds containing a hydroxyl group in any of the formulas disclosed herein are, for example, pharmaceutically acceptable esters or ethers that are cleavable in vivo in a human or animal body to produce a parent hydroxyl compound. Suitable pharmaceutically acceptable ester-forming groups of the hydroxyl group include inorganic esters such as phosphate esters (including phosphoramide cyclic esters). Other suitable pharmaceutically acceptable ester-forming groups of the hydroxyl group include C1-C1 esters. 10 Alkyl groups such as acetyl, benzoyl, phenylacetyl, and substituted benzoyl and phenylacetyl groups, C1-C 10Alkoxycarbonyl groups include ethoxycarbonyl, N,N-(C1-C6 alkyl)2-carbamoyl, 2-dialkylaminoacetyl, and 2-carboxyacetyl. Examples of cyclic substituents on the phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazine-1-ylmethyl, and 4-(C1-C4 alkyl)piperazine-1-ylmethyl. Suitable pharmaceutically acceptable ether-forming groups for the hydroxyl group include α-acyloxyalkyl groups such as acetoxymethyl and neopentyloxymethyl.
[0524] Suitable pharmaceutically acceptable prodrugs of compounds having a carboxyl group of any of the formulas disclosed herein are, for example, amides that are cleavable in vivo, such as those with amines such as ammonia, C 1-4 Alkylamines such as methylamine, (C1-C4 alkyl)2amines such as dimethylamine, N-ethyl-N-methylamine or diethylamine, C1-C4 alkoxy-C2-C4 alkylamines such as 2-methoxyethylamine, phenyl-C1-C4 alkylamines such as benzylamine, and amides formed from amino acids such as glycine or their esters.
[0525] Suitable pharmaceutically acceptable prodrugs of compounds having an amino group of any of the formulas disclosed herein are, for example, amide derivatives that are cleavable in vivo. Suitable pharmaceutically acceptable amides derived from an amino group include, for example, those with C1-C2 groups. 10 Alkyl groups include acetyl, benzoyl, phenylacetyl, and amides formed by substituted benzoyl and phenylacetyl groups. Examples of cyclic substituents on phenylacetyl and benzoyl groups include aminomethyl, N-alkylaminomethyl, N,N-dialkylaminomethyl, morpholinomethyl, piperazine-1-ylmethyl, and 4-(C1-C4 alkyl)piperazine-1-ylmethyl.
[0526] The in vivo effects of any compound of any formula disclosed herein may be exerted in part by one or more metabolites formed in a human or animal following administration of any compound of any formula disclosed herein. As described above, the in vivo effects of any compound of any formula disclosed herein may also be exerted through the metabolism of a prodrug.
[0527] As appropriate, this disclosure excludes any individual compound that does not have the biological activity defined herein.
[0528] Synthesis method In some respects, this disclosure provides a method for preparing the compounds of this disclosure.
[0529] In some respects, this disclosure provides a method for preparing a compound, comprising one or more steps as described herein.
[0530] In some respects, this disclosure provides compounds that are obtainable, acquired, or directly obtained by methods used to prepare compounds as described herein.
[0531] In some respects, this disclosure provides intermediates as described herein, which are suitable for use in methods for preparing compounds as described herein.
[0532] The compounds of this disclosure can be prepared using any suitable technique known in the art. Specific methods for preparing these compounds are further described in the accompanying examples.
[0533] In the description of the synthetic methods described herein and any reference synthetic methods used to prepare the starting materials, it should be understood that all suggested reaction conditions, including the choice of solvent, reaction atmosphere, reaction temperature, experimental duration and post-treatment procedures, can be selected by those skilled in the art.
[0534] Those skilled in the field of organic synthesis will understand that the functional groups present on various parts of a molecule must be compatible with the reagents and reaction conditions used.
[0535] It should be understood that in the process of synthesizing the compounds disclosed herein using the methods defined herein, or in the synthesis of certain starting materials, it may be desirable to protect certain substituents to prevent them from undesirable reactions. A skilled chemist will understand when such protection is necessary, and how such protecting groups can be placed and subsequently removed. For examples of protecting groups, see one of the many general texts on the subject, such as Theodora Green's "Protective Groups in Organic Synthesis" (published by John Wiley & Sons). Protecting groups can be removed by any convenient method described in the literature or known to a skilled chemist suitable for removing the protecting groups in question, choosing such a method to achieve the removal of the protecting groups with minimal interference to groups elsewhere in the molecule. Therefore, if the reactants include, for example, groups such as amino, carboxyl, or hydroxyl groups, it may be necessary to protect these groups in some of the reactions mentioned herein.
[0536] As examples, suitable protecting groups for amino or alkylamino groups are, for example, acyl groups, such as alkanoyl groups like acetyl groups, alkoxycarbonyl groups like methoxycarbonyl, ethoxycarbonyl, or tert-butoxycarbonyl groups, arylmethoxycarbonyl groups like benzyloxycarbonyl groups, or aromatic acyl groups like benzoyl groups. The deprotection conditions for these protecting groups necessarily vary depending on the choice of protecting group. Therefore, for example, acyl groups such as alkanoyl, alkoxycarbonyl, or aromatic acyl groups can be removed by hydrolysis, for example, with a suitable base (such as an alkali metal hydroxide, such as lithium hydroxide or sodium hydroxide). Alternatively, acyl groups such as tert-butoxycarbonyl groups can be removed, for example, by treatment with a suitable acid (such as hydrochloric acid, sulfuric acid, or phosphoric acid or trifluoroacetic acid), and arylmethoxycarbonyl groups such as benzyloxycarbonyl groups can be removed, for example, by hydrogenation with a catalyst (such as carbon-supported palladium) or by treatment with a Lewis acid such as tri(trifluoroacetic acid)boron. Suitable alternative protecting groups for primary amino groups are, for example, phthaloyl groups, which can be removed by treatment with alkylamines (e.g., dimethylaminopropylamine) or with hydrazine.
[0537] Suitable protecting groups for the hydroxyl group are, for example, acyl groups, such as alkanoyl groups like acetyl, aromatic acyl groups like benzoyl, or arylmethyl groups like benzyl. The deprotection conditions for these protecting groups necessarily vary depending on the choice of protecting group. Therefore, for example, acyl groups such as alkanoyl or aromatic acyl groups can be removed by hydrolysis with a suitable base such as an alkali metal hydroxide (e.g., lithium hydroxide, sodium hydroxide) or ammonia. Alternatively, arylmethyl groups such as benzyl can be removed by hydrogenation, for example, via a catalyst (e.g., palladium supported on carbon).
[0538] Suitable protecting groups for the carboxyl group are, for example, esterification groups, such as methyl or ethyl, which can be removed by hydrolysis, for example, with a base (such as sodium hydroxide), or, for example, tert-butyl, which can be removed by treatment with an acid (such as an organic acid such as trifluoroacetic acid), or, for example, benzyl, which can be removed by hydrogenation, for example, with a catalyst (such as carbon-supported palladium).
[0539] Once a compound of formula (I) has been synthesized by any of the methods defined herein, the method may further include the following additional steps: (i) removing any protecting groups present; (ii) converting a compound of formula (I) into another compound of formula (I); (iii) forming a pharmaceutically acceptable salt, hydrate or solvate thereof; and / or (iv) forming a prodrug thereof.
[0540] The resulting compound of formula (I) can be isolated and purified using techniques well known in the art.
[0541] Conveniently, the reaction of the compounds is carried out in the presence of a suitable solvent, which is preferably inert under its respective reaction conditions. Examples of suitable solvents include, but are not limited to, hydrocarbons such as hexane, petroleum ether, benzene, toluene, or xylene; chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, tetrachloromethane, chloroform, or dichloromethane; alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol, or tert-butanol; ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF), 2-methyltetrahydrofuran, cyclopentylmethyl ether (CPME), methyl tert-butyl ether (MTBE), or dioxane; ethylene glycol ethers, Such as ethylene glycol monomethyl ether or monoethyl ether or ethylene glycol dimethyl ether (diethylene glycol dimethyl ether); ketones such as acetone, methyl isobutyl ketone (MIBK) or butanone; amides such as acetamide, dimethylacetamide, dimethylformamide (DMF) or N-methylpyrrolidone (NMP); nitriles such as acetonitrile; sulfoxides such as dimethyl sulfoxide (DMSO); nitro compounds such as nitromethane or nitrobenzene; esters such as ethyl acetate or methyl acetate, or mixtures of said solvents or mixtures with water.
[0542] The reaction temperature is appropriately between about -100°C and 300°C, depending on the reaction steps and the conditions used.
[0543] Reaction times typically range from less than a minute to several days, depending on the reactivity of the various compounds and the reaction conditions. Suitable reaction times can be readily determined using methods known in the art, such as reaction monitoring. Based on the reaction temperatures given above, suitable reaction times generally range from 10 minutes to 48 hours.
[0544] Furthermore, other compounds of this disclosure can be readily prepared using the procedures described herein in conjunction with common techniques in the art. Those skilled in the art will readily understand that these compounds can be prepared using known modifications to the conditions and methods of the following preparation procedures.
[0545] As those skilled in the art of organic synthesis will understand, the compounds of this disclosure can be readily obtained by a variety of synthetic routes, some of which are illustrated in the accompanying examples. Those skilled in the art will readily recognize which reagents and reaction conditions to use and how to apply and modify them in any particular case (whenever necessary or useful) to obtain the compounds of this disclosure. Furthermore, some compounds of this disclosure can be readily synthesized by reacting other compounds of this disclosure under suitable conditions, for example, by applying standard synthetic methods such as reduction, oxidation, addition, or substitution reactions, to convert a particular functional group present in a compound of this disclosure or a suitable precursor molecule into another; these methods are well known to those skilled in the art. Likewise, those skilled in the art will apply (whenever necessary or useful) synthetic protecting (or protective) groups; suitable protecting groups and methods for introducing and removing them are well known to those skilled in the art of chemical synthesis and are described in more detail, for example, in PGM Wuts, TW Greene, “Greene's Protective Groups in Organic Synthesis,” 4th edition (2006) (John Wiley & Sons).
[0546] The general routes for preparing the compounds of this application are described in Schemes 1-5 herein.
[0547] Option 1 Compound V can be prepared from compound I according to the method shown in Scheme 1. Compound I can be generated from commercially available materials according to the route previously reported in WO2019 / 027058, or according to a similar method. Hal used herein refers to a halogen atom.
[0548] Examples of amino protecting groups represented by P1 include urethane-type protecting groups such as tert-butyl urethane. When Y is oxygen, compound II can be commercially available or prepared from commercially available materials via alkylation or the Mitsunobu reaction. B represents boric acid or borate esters, etc.
[0549] When X is nitrogen, examples of protecting groups represented by P2 include phthalamide-type protecting groups. When X is carbon or oxygen, examples of protecting groups represented by P2 include carboxyl protecting groups such as methyl esters and ethyl esters.
[0550] Compound III can be generated by a palladium-mediated Suzuki-type cross-coupling reaction between compound I and compound II. Examples of metal catalysts that can be used in the coupling reaction include palladium compounds such as palladium acetate (II), tetrakis(triphenylphosphine)palladium (O), dichlorobis(triphenylphosphine)-palladium (II), tris(dibenzylacetone)dipalladium (O), 1,1'-bis(diphenylphosphine)-ferrocene palladium dichloride (II), and (2-dicyclohexylphosphine-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]methanesulfonate (II). Additionally, a base can be added to the reaction system, and examples include inorganic bases.
[0551] Compound IV can be generated by removing the protecting groups represented by P1 and P2 using methods known to them, such as by using acids, bases or nucleophiles (such as hydrazine), reduction methods, etc.
[0552] Compound V can be generated by circumferentially closing compound IV. Examples of reagents used when circumferentially closing the ring include activated carboxylic acids such as acid anhydrides, activated esters, and activated carbamates. Examples of activators of carboxylic acids include carbodiimide condensing agents such as... N -(3-Dimethylaminopropyl)- N Examples of suitable condensing agents include '-ethylcarbodiimide hydrochloride (EDCI); carbonate condensing agents such as 1,1-carbonyldiimidazole (CDI), triphosgene, etc.; O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethylureon hexafluorophosphate (HATU); and combinations thereof. Additionally, a base can be added to the reaction system. Examples of bases include inorganic bases and organic bases. When using a carbodiimide condensing agent, further additives such as 1-hydroxybenzotriazole (HOBt), dimethylaminopyridine (DMAP), etc., can be added to the reaction system.
[0553] Option 2 Alternatively, compound V can be generated from compound I according to the method shown in reaction scheme 2. Compound VI can be generated by palladium-mediated cross-coupling Suzuki-type reaction of compound I, arylboronic acid or arylboronic ester, etc. Examples of metal catalysts to be used when carrying out the coupling reaction in each step include palladium compounds such as palladium acetate (II), tetrakis(triphenylphosphine)palladium (O), dichlorobis(triphenylphosphine)palladium (II), tris(dibenzylacetone)palladium (O), 1,1'-bis(diphenylphosphine)ferrocene palladium dichloride (II), (2-dicyclohexylphosphine-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]methanesulfonate (II), etc. In addition, a base can be added to the reaction system, and examples of such bases include inorganic bases, etc. Examples of the "leaving group" represented by LG1 include halogen atoms, optionally including halogenated C atoms. 1-6 Alkyl sulfonyloxy groups (e.g., methanesulfonyloxy, ethanesulfonyloxy, trifluoromethanesulfonyloxy), etc.
[0554] By using a metal catalyst to carry out a Sonogashira-type cross-coupling reaction between compound VI and a suitable acetylene (commercially available or obtainable by known methods), compound VII, where Y is carbon, can be generated. Examples of metal catalysts to be used include palladium compounds such as palladium(II) acetate, tetra(triphenylphosphine)palladium(O), dichlorobis(triphenylphosphine)palladium(II), and bis(acetonitrile)palladium(II) dichloride. Phosphine ligands such as 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (XPhos) and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos) can also be added to the reaction system. Additionally, a base can be added to the reaction system, examples of which include inorganic bases.
[0555] Compound VIII can be generated by the reduction of compound VII. When carbon-carbon double or triple bonds are reduced, they can be combined with hydrogen using catalysts such as palladium-carbon or Lindlar catalysts.
[0556] Compound VIII, where Y is oxygen and LG1 represents a hydroxyl group, can be directly prepared from compound VI by performing a Mitsunobu reaction using commercially available materials. When performing the Mitsunobu reaction in each step, azodicarbonate esters (e.g., diethyl azodicarbonate (DEAD), diisopropyl azodicarbonate (DIAD), etc.) and triphenylphosphine are used as reagents.
[0557] Compound IV can be generated by removing the protecting groups represented by P1 and P2 using known methods, such as methods using acids, bases, hydrazine, or reduction methods.
[0558] Compound V can be generated through a ring-closing reaction as shown in reaction scheme 1.
[0559] Compound V can also be prepared by the closed-ring metathesis reaction scheme outlined in Schemes 3-5.
[0560] Option 3 Compound IX can be generated by removing the protecting group represented by P1 from compound (I) using appropriate known methods, such as by using acids, bases, hydrazine, or reduction methods.
[0561] Compound XI can be generated by condensing compound IX and compound X. LG2 is a suitable leaving group. Examples of reagents used in the condensation reaction include activated carboxylic acids such as acid anhydrides, activated esters, activated carbonates, activated carbamates, isocyanates, etc. Examples of activators of carboxylic acids include carbodiimide condensing agents such as… N -(3-Dimethylaminopropyl)- N ′-Ethylcarbodiimide hydrochloride (EDCI); carbonate condensing agents such as 1,1-carbonyldiimidazole (CDI), triphosgene, etc.; O-(7-azabenzotriazol-l-yl)-N,N,N',N'-tetramethylureonium hexafluorophosphate (HATU); combinations thereof, etc. Additionally, a base can be added to the reaction system. Examples of bases include inorganic bases, organic bases, etc. When using a carbodiimide condensing agent, additives such as 1-hydroxybenzotriazole (HOBt) or dimethylaminopyridine (DMAP) can be further added to the reaction system. Compound X can be commercially available or generated from commercially available materials by methods known per se or similar methods. L1 represents C 1-5 Allyl, allyloxy, etc. Examples of leaving groups represented by LG2 include halogen atoms, optionally including halocarbons. 1-6 Alkyl sulfonyloxy groups (e.g., methanesulfonyloxy, ethanesulfonyloxy, trifluoromethane-sulfonyloxy), p-nitrophenol, etc.
[0562] Compound XII may be commercially available or generated from commercially available materials by methods known per se or similar methods. B represents boric acid, ester, etc. L1 represents C. 1-3 Allyl, etc.
[0563] Compound XIII can be generated by subjecting a combination of compounds XI and XII to the aforementioned palladium-mediated cross-coupling Suzuki-type reaction as shown in Scheme 1.
[0564] Option 4 Compound XIII can be generated by subjecting a combination of compound I and compound XII to the aforementioned palladium-mediated cross-coupling Suzuki-type reaction as shown in Scheme 1.
[0565] Compound XIV can be generated by removing the protecting group represented by P1 using known methods, such as by using acids, bases, hydrazine, or reduction methods.
[0566] Compound XIII can be generated by subjecting compound XIV and compound X to a condensation reaction as described above in Scheme 3.
[0567] Option 5 Compound XIV can be generated by circumferentially closing compound XIII. Examples of catalysts that can be used when circumferentially closing the ring via a metathesis reaction include ruthenium compounds such as Grubbs I, Grubbs II, and HoveydaGrubbs.
[0568] Compound V can be generated by reducing compound XIV. When the carbon-carbon double bond is reduced, it can be done with hydrogen using catalysts such as palladium-carbon or Lindlar catalysts.
[0569] Biological assay Once compounds designed, selected, and / or optimized using the methods described above are generated, they can be characterized using a variety of assays known to those skilled in the art to determine whether the compounds possess biological activity. For example, the molecules can be characterized by conventional assays, including, but not limited to, those described below, to determine whether they possess predicted activity, binding activity, and / or binding specificity.
[0570] Furthermore, high-throughput screening can be used to accelerate analyses using such assays. Therefore, the activity of molecules described herein can be rapidly screened using techniques known in the art. General methods for performing high-throughput screening are described, for example, in Devlin (1998). High Throughput Screening Marcel Dekker; and U.S. Patent No. 5,763,263. High-throughput assays can use one or more different assay techniques, including, but not limited to, those listed below.
[0571] Various in vitro or in vivo biological assays can be applied to detect the effects of the compounds disclosed herein. These in vitro or in vivo biological assays may include, but are not limited to, enzyme activity assays, electrophoretic mobility variation assays, reporter gene assays, in vitro cell viability assays, and the assays described herein.
[0572] Despite the loss of orexinocytes and reduction of orexin peptides in the cerebrospinal fluid within NT1, the orexin receptors on postsynaptic neurons remain intact, making them suitable targets for pharmacological intervention. Orexin peptides A and B (OXA and OXB) can be cleaved from a single precursor molecule (proorexin) produced only in the lateral hypothalamus. Both orexin peptides bind to OX2R with similar high affinity, but the orexin-1 receptor (OX1R) is preferentially bound to OXA. Postsynaptic activation of these G protein-coupled orexin receptors stimulates the release of monoaminergic and cholinergic neurotransmitters that promote wakefulness and inhibitory neurotransmitters that suppress REM sleep relaxation.
[0573] In some implementations, the biological assays are described in the embodiments herein.
[0574] In some embodiments, the bioassay is a measurement of the agonist activity of the compound on cells expressing human orexin type 2 or human orexin type 1 receptors.
[0575] In some embodiments, the assay includes preparing Chinese hamster ovary (CHO) cells expressing human orexin type 2 receptor (hOX2R) or human orexin type 1 receptor (hOX1R).
[0576] Pharmaceutical Composition In some aspects, this disclosure provides a pharmaceutical composition comprising a compound of this disclosure as an active ingredient. In some embodiments, this disclosure provides a pharmaceutical composition comprising at least one compound of the various types described herein, or a pharmaceutically acceptable salt or solvate thereof, and one or more pharmaceutically acceptable carriers or excipients. In some embodiments, this disclosure provides a pharmaceutical composition comprising at least one compound selected from Tables A1, A2, B1, and B2.
[0577] The term “composition” as used herein is intended to include products containing specified amounts of specified ingredients, and any products directly or indirectly produced from combinations of specified amounts of specified ingredients.
[0578] The compounds of this disclosure can be formulated for oral administration in forms such as tablets, capsules (each including sustained-release or time-release formulations), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions. The compounds of this disclosure can also be formulated for intravenous (bolus or infusion), intraperitoneal, topical, subcutaneous, intramuscular, or transdermal (e.g., patch) administration, all in forms well known to those skilled in the pharmaceutical art.
[0579] The formulations disclosed herein may be in the form of an aqueous solution comprising an aqueous medium. The aqueous medium component may comprise water and at least one pharmaceutically acceptable excipient. Suitable acceptable excipients include those selected from: solubilizers, chelating agents, preservatives, tensioning agents, viscosity / suspending agents, buffers, and pH adjusters, and mixtures thereof.
[0580] Any suitable solubilizer can be used. Examples of solubilizers include cyclodextrins, such as those selected from: hydroxypropyl-β-cyclodextrin, methyl-β-cyclodextrin, randomly methylated β-cyclodextrin, ethylated β-cyclodextrin, triacetyl-β-cyclodextrin, fully acetylated β-cyclodextrin, carboxymethyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, 2-hydroxy-3-(trimethylammonium)propyl-β-cyclodextrin, glucosyl-β-cyclodextrin, sulfated β-cyclodextrin (S-β-CD), maltosyl-β-cyclodextrin, β-cyclodextrin sulfonyl ether, branched-chain β-cyclodextrin, hydroxypropyl-γ-cyclodextrin, randomly methylated γ-cyclodextrin and trimethyl-γ-cyclodextrin, and mixtures thereof.
[0581] Any suitable chelating agent can be used. Examples of suitable chelating agents include those selected from the following: ethylenediaminetetraacetic acid and its metal salts, disodium edetate, trisodium edetate and tetrasodium edetate and mixtures thereof.
[0582] Any suitable preservative may be used. Examples of preservatives include those selected from the following: quaternary ammonium salts such as benzalkonium halide (preferably benzalkonium chloride), chlorhexidine gluconate, benzyl chloride, cetylpyridinium chloride, benzyl bromide, phenylmercuric nitrate, phenylmercuric acetate, phenylmercuric neodecanoate, thimerosal, methylparaben, propylparaben, sorbic acid, potassium sorbate, sodium benzoate, sodium propionate, ethylparaben, propylaminopropyl biguanide, and butylparaben and sorbic acid, and mixtures thereof.
[0583] The aqueous medium may also include a tensioning agent to adjust the tension (osmotic pressure). The tensioning agent may be selected from glycols (such as propylene glycol, diethylene glycol, triethylene glycol), glycerol, dextrose, glycerol, mannitol, potassium chloride, and sodium chloride, and mixtures thereof.
[0584] The aqueous medium may also contain a viscosity / suspending agent. Suitable viscosity / suspending agents include those selected from: cellulose derivatives, such as methylcellulose, ethylcellulose, hydroxyethylcellulose, polyethylene glycol (such as polyethylene glycol 300, polyethylene glycol 400), carboxymethylcellulose, hydroxypropyl methylcellulose, and crosslinked acrylic polymers (carbomers), such as acrylic polymers crosslinked with polyolefin ethers or divinyl glycol (carbomers—such as carbomer 934, carbomer 934P, carbomer 971, carbomer 974 and carbomer 974P) and mixtures thereof.
[0585] To adjust the formulation to an acceptable pH (typically a pH range of about 5.0 to about 9.0, more preferably about 5.5 to about 8.5, particularly about 6.0 to about 8.5, about 7.0 to about 8.5, about 7.2 to about 7.7, about 7.1 to about 7.9, or about 7.5 to about 8.0), the formulation may contain a pH adjuster. The pH adjuster is typically an inorganic acid or a metal hydroxide base selected from potassium hydroxide, sodium hydroxide, and hydrochloric acid, and mixtures thereof, preferably sodium hydroxide and / or hydrochloric acid. These acidic and / or basic pH adjusters are added to adjust the formulation to an acceptable target pH range. Therefore, it may not be necessary to use both an acid and a base simultaneously—depending on the formulation, adding either an acid or a base may be sufficient to bring the mixture to the desired pH range.
[0586] The aqueous medium may also contain a buffer to stabilize the pH. When used, the buffer is selected from the following: phosphate buffers (such as sodium dihydrogen phosphate and disodium hydrogen phosphate), borate buffers (such as boric acid or its salts, including disodium tetraborate), citrate buffers (such as citric acid or its salts, including sodium citrate), and ε-aminocaproic acid, and mixtures thereof.
[0587] The formulation may further comprise a wetting agent. Suitable classes of wetting agents include those selected from: polyoxypropylene-polyoxyethylene block copolymers (poloxam), polyethoxylated ethers of castor oil, polyoxyethylene-modified sorbitol esters (polysorbates), oxyethylated octylphenol polymers (teroxam), polyoxyethylene 40 stearate, ethylene glycol esters of fatty acids, glyceryl esters of fatty acids, sucrose fatty acid esters and polyoxyethylene fatty acid esters, and mixtures thereof.
[0588] Oral compositions typically include an inert diluent or an edible, pharmaceutically acceptable carrier. They may be encapsulated in gelatin capsules or compressed into tablets. For oral therapeutic administration, the active compound may be blended with excipients and used in tablet, lozenge, or capsule form. Oral compositions may also be prepared using a liquid carrier for use as a mouthwash, wherein the compound in the fluid carrier is administered orally and by rinsing and spitting or swallowing. Pharmaceutically compatible binders and / or excipients may be included as part of the composition. The tablets, pills, capsules, lozenges, etc., may contain any of the following components or compounds with similar properties: binders such as microcrystalline cellulose, tragacanth gum, or gelatin; excipients such as starch or lactose; disintegrants such as alginate, Primogel, or corn starch; lubricants such as magnesium stearate or sterotes; gliding agents such as colloidal silica; sweeteners such as sucrose or saccharin; or flavoring agents such as peppermint, methyl salicylate, or orange flavoring.
[0589] According to another aspect of this disclosure, a pharmaceutical composition is provided comprising a compound of the present disclosure as defined above, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and a pharmaceutically acceptable diluent or carrier.
[0590] The compositions disclosed herein may be in forms suitable for use as follows: oral administration (e.g., as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), topical administration (e.g., as creams, ointments, gels, or aqueous or oily solutions or suspensions), administration by inhalation (e.g., as finely pulverized powders or liquid aerosols), administration by blowing (e.g., as finely pulverized powders), or parenteral administration (e.g., as sterile aqueous or oily solutions for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular administration, or as suppositories for rectal administration).
[0591] The compositions of this disclosure can be obtained through conventional procedures using conventional pharmaceutical excipients, as is well known in the art. Therefore, compositions intended for oral use may contain, for example, one or more colorants, sweeteners, flavorings, and / or preservatives.
[0592] An effective amount of the compound of this disclosure for use in therapy is sufficient to treat or prevent the inflammasome-related conditions mentioned herein, slow their progression, and / or alleviate symptoms associated with said conditions.
[0593] An effective amount of the compound of this disclosure for use in therapy is sufficient to treat the inflammasome-related conditions mentioned herein, slow their progression, and / or alleviate symptoms associated with said conditions.
[0594] The dosage of compounds of formula (I) used for therapeutic or preventative purposes will naturally vary according to well-known medical principles, the nature and severity of the condition, the age and sex of the animal or patient, and the route of administration.
[0595] How to use In some respects, this disclosure provides a method for modulating orexin-2 receptor activity (e.g., in vitro or in vivo), the method comprising contacting cells with an effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof.
[0596] In some respects, this disclosure provides a method for treating or preventing a disease or disorder disclosed herein in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0597] In some respects, this disclosure provides a method for treating a disease or disorder disclosed herein in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0598] In some embodiments, the disease or disorder is associated with orexin receptor activity. In some embodiments, the disease or disorder is one in which orexin receptor activity is involved.
[0599] In some embodiments, the disease or disorder is associated with orexin-2 receptor activity. In some embodiments, the disease or disorder is one in which orexin-2 receptor activity is involved.
[0600] In some implementations, the disease or disorder is a symptom of narcolepsy, excessive sleep disorder, neurodegenerative disorder, rare genetic disorder, mental health disorder, metabolic syndrome, osteoporosis, heart failure, coma, or complications from anesthesia recovery.
[0601] In some respects, this disclosure provides a method for treating or preventing symptoms of narcolepsy, excessive sleep disorder, neurodegenerative disorder, rare genetic disorder, mental health disorder, metabolic syndrome, osteoporosis, heart failure, coma, or complications of anesthesia recovery in subjects in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0602] In some respects, this disclosure provides a method for treating symptoms of narcolepsy, excessive sleep disorder, neurodegenerative disorder, rare genetic disorder, mental health disorder, metabolic syndrome, osteoporosis, heart failure, coma, or complications of anesthesia recovery in subjects with such need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0603] In some aspects, this disclosure provides a method for treating or preventing narcolepsy in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0604] In some respects, this disclosure provides a method for treating or preventing excessive sleep disorder in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0605] In some respects, this disclosure provides a method for treating or preventing neurodegenerative disorders in subjects in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0606] In some respects, this disclosure provides a method for treating or preventing symptoms of a rare genetic disorder in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0607] In some respects, this disclosure provides a method for treating or preventing mental health disorders in subjects in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0608] In some aspects, this disclosure provides a method for treating or preventing metabolic syndrome in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0609] In some respects, this disclosure provides a method for treating or preventing osteoporosis in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0610] In some aspects, this disclosure provides a method for treating or preventing heart failure in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0611] In some respects, this disclosure provides a method for treating or preventing coma in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0612] In some respects, this disclosure provides a method for treating or preventing complications of anesthesia recovery in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0613] In some aspects, this disclosure provides a method for treating narcolepsy in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0614] In some respects, this disclosure provides a method for treating excessive sleep disorder in a subject with such need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0615] In some aspects, this disclosure provides a method for treating neurodegenerative disorders in subjects in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0616] In some respects, this disclosure provides a method for treating symptoms of a rare genetic disorder in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0617] In some respects, this disclosure provides a method for treating mental health disorders in subjects with such need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0618] In some aspects, this disclosure provides a method for treating metabolic syndrome in a subject with this need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0619] In some aspects, this disclosure provides a method for treating osteoporosis in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0620] In some respects, this disclosure provides a method for treating heart failure in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0621] In some aspects, this disclosure provides a method for treating coma in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0622] In some aspects, this disclosure provides a method for treating complications of anesthesia recovery in a subject in need, the method comprising administering to the subject a therapeutically effective amount of a compound of this disclosure or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of this disclosure.
[0623] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for modulating orexin receptor activity (e.g., in vitro or in vivo).
[0624] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for modulating orexin-2 receptor activity (e.g., in vitro or in vivo).
[0625] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment or prevention of the diseases or disorders disclosed herein.
[0626] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment of diseases or disorders disclosed herein.
[0627] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment or prevention of symptoms of narcolepsy, excessive sleep disorder, neurodegenerative disorder, rare genetic disorder, mental health disorder, metabolic syndrome, osteoporosis, heart failure, coma, or complications of anesthesia recovery in subjects with such need.
[0628] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment or prevention of narcolepsy in subjects in need of such treatment.
[0629] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating or preventing excessive sleep disorder in subjects in need of such treatment.
[0630] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment or prevention of neurodegenerative disorders in subjects in need of such treatment.
[0631] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment or prevention of symptoms of rare genetic disorders in subjects in need of such treatment.
[0632] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating or preventing mental health disorders in subjects in need of such treatment.
[0633] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in the treatment or prevention of metabolic syndrome in subjects in need of such treatment.
[0634] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment or prevention of osteoporosis in subjects in need of such treatment.
[0635] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating or preventing heart failure in subjects in need of such treatment.
[0636] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating or preventing coma in subjects in need of such treatment.
[0637] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating or preventing complications of anesthesia recovery in subjects in need of such treatment.
[0638] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating, in subjects with need, symptoms of narcolepsy, excessive sleep disorder, neurodegenerative disorders, rare genetic disorders, mental health disorders, metabolic syndrome, osteoporosis, heart failure, coma, or complications of anesthesia recovery.
[0639] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating narcolepsy in subjects in need of such treatment.
[0640] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating excessive sleep disorder in subjects with such need.
[0641] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating neurodegenerative disorders in subjects in need of such treatment.
[0642] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment of symptoms of rare genetic disorders in subjects in need of such treatment.
[0643] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating mental health disorders in subjects in need of such treatment.
[0644] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating metabolic syndrome in subjects with such need.
[0645] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for the treatment of osteoporosis in subjects in need of such treatment.
[0646] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating heart failure in subjects in need of such treatment.
[0647] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating coma in subjects in need of such treatment.
[0648] In some respects, this disclosure provides compounds of this disclosure or pharmaceutically acceptable salts thereof for use in treating complications of anesthesia recovery in subjects in need of such treatment.
[0649] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for regulating orexin activity (e.g., in vitro or in vivo).
[0650] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for regulating orexin-2 activity (e.g., in vitro or in vivo).
[0651] In some respects, this disclosure provides for the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of the diseases or disorders disclosed herein.
[0652] In some respects, this disclosure provides for the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of the diseases or disorders disclosed herein.
[0653] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of symptoms of narcolepsy, excessive sleep disorder, neurodegenerative disorders, rare genetic disorders, mental health disorders, metabolic syndrome, osteoporosis, heart failure, coma, or complications of anesthesia recovery in subjects with such need.
[0654] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of narcolepsy in subjects in need of such treatment.
[0655] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of excessive sleep disorder in subjects in need of such treatment.
[0656] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of neurodegenerative disorders in subjects in need of such treatment.
[0657] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of symptoms of rare genetic disorders in subjects in need of such treatment.
[0658] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of mental health disorders in persons in need of such treatment.
[0659] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of metabolic syndrome in subjects in need of such treatment.
[0660] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of osteoporosis in subjects in need of such treatment.
[0661] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of heart failure in subjects in need of such treatment.
[0662] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of coma in subjects in need of such treatment.
[0663] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment or prevention of complications of anesthesia recovery in subjects in need of such treatment.
[0664] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment in subjects with a need of symptoms of narcolepsy, excessive sleep disorder, neurodegenerative disorder, rare genetic disorder, mental health disorder, metabolic syndrome, osteoporosis, heart failure, coma, or complications of anesthesia recovery.
[0665] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of narcolepsy in subjects in need of such treatment.
[0666] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for treating excessive sleep disorder in subjects in need of such treatment.
[0667] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of neurodegenerative disorders in subjects in need of such treatment.
[0668] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for treating symptoms of rare genetic disorders in subjects in need of such treatment.
[0669] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of mental health disorders in subjects in need of such treatment.
[0670] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of metabolic syndrome in subjects in need of such treatment.
[0671] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of osteoporosis in subjects in need of such treatment.
[0672] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of heart failure in subjects in need of such treatment.
[0673] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of coma in subjects in need of such treatment.
[0674] In some respects, this disclosure provides the use of the compounds of this disclosure or pharmaceutically acceptable salts thereof in the preparation of medicaments for the treatment of complications of anesthesia recovery in subjects in need of such treatment.
[0675] This disclosure provides compounds that function as regulators of orexin receptor activity.
[0676] In some embodiments, the compounds disclosed herein are agonists of orexin receptors.
[0677] This disclosure provides compounds that function as regulators of orexin-2 receptor activity.
[0678] In some embodiments, the compounds disclosed herein are agonists of the orexin-2 receptor.
[0679] In some embodiments, the regulation of the orexin receptor is the activation of the orexin receptor.
[0680] The efficacy of the compounds disclosed herein can be determined using industry-accepted assays / disease models, based on standard practices that elucidate them as described in the art and found in current general knowledge.
[0681] This disclosure also provides a method for treating a disease or disorder involving orexin receptor activity in a patient requiring such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound as defined herein or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0682] This disclosure also provides a method for treating a disease or disorder involving orexin-2 receptor activity in a patient requiring such treatment, the method comprising administering to the patient a therapeutically effective amount of a compound as defined herein or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
[0683] In some embodiments, this disclosure also provides a method for treating a disease or disorder by reducing excessive sleepiness and / or excessive daytime sleepiness.
[0684] In some implementations, this disclosure also provides a method for treating a disease or disorder by reducing excessive sleepiness.
[0685] In some implementations, this disclosure also provides a method for treating a disease or disorder by reducing excessive daytime sleep.
[0686] In some implementations, the disease or disorder is associated with excessive sleepiness and / or excessive daytime sleepiness.
[0687] In some implementations, the disease or disorder is primary hypersomnia disorder, neurodegenerative disorder, symptoms of hypersomnia / neurodegenerative disorder, symptoms of rare genetic disorders, mental health disorder, metabolic syndrome, osteoporosis, heart failure, coma, or anesthesia recovery.
[0688] In some implementations, the disease or disorder is primary hypersomnia disorder, neurodegenerative disorder, symptoms of hypersomnia / neurodegenerative disorder, symptoms of rare genetic disorders, mental health disorder, metabolic syndrome, osteoporosis, heart failure, coma, or complications from anesthesia recovery.
[0689] In some implementations, excessive daytime sleep is associated with neurodegenerative disorders.
[0690] In some implementations, the neurodegenerative disorder associated with excessive daytime sleepiness is Parkinson's disease, Alzheimer's disease, Huntington's disease, or multiple sclerosis.
[0691] In some implementations, the disease or disorder is a recurrence of excessive sleepiness.
[0692] In some implementations, the recurrence of excessive sleep is narcolepsy type 1, narcolepsy type 2, or idiopathic excessive sleep.
[0693] In some implementations, the disease or disorder is sleep apnea, traumatic brain injury, age-related cognitive impairment, or excessive daytime sleepiness.
[0694] In some implementations, excessive daytime sleepiness is associated with sleep apnea, traumatic brain injury, or age-related cognitive impairment.
[0695] In some embodiments, the disorder is narcolepsy. In some embodiments, the narcolepsy is type 1 narcolepsy. In some embodiments, the narcolepsy is type 2 narcolepsy.
[0696] In some implementations, the excessive sleep is a symptom of narcolepsy.
[0697] In some implementations, the disease or disorder is a symptom of narcolepsy.
[0698] In some implementations, the symptoms of narcolepsy include excessive daytime sleepiness, cataplexy, sleep paralysis, hallucinations of being half-awake and half-asleep, nighttime sleep disturbances, or inappropriate timing of rapid eye movement (REM) sleep.
[0699] In some implementations, the symptom of narcolepsy is excessive daytime sleepiness.
[0700] In some embodiments, the symptom of narcolepsy is cataplexy. In some embodiments, cataplexy is a characteristic symptom of narcolepsy (e.g., narcolepsy type 1).
[0701] In some implementations, the symptom of narcolepsy is sleep paralysis.
[0702] In some implementations, the symptoms of narcolepsy are semi-awake and semi-sleep hallucinations.
[0703] In some implementations, the symptoms of narcolepsy are nocturnal sleep disturbances.
[0704] In some implementations, the symptoms of narcolepsy are inappropriate periods of rapid eye movement (REM) sleep.
[0705] In some implementations, the neurodegenerative disorder is characterized by sudden collapse.
[0706] In some implementations, the neurodegenerative disorder is characterized by excessive daytime sleepiness.
[0707] In some implementations, the neurodegenerative disorder is Parkinson's disease.
[0708] In some implementations, the neurodegenerative disorder is Alzheimer's disease.
[0709] In some implementations, the neurodegenerative disorder is Huntington's disease.
[0710] In some implementations, the neurodegenerative disorder is multiple sclerosis.
[0711] In some implementations, the neurodegenerative disorder is traumatic brain injury.
[0712] In some implementations, the neurodegenerative disorder is sleep apnea.
[0713] In some implementations, the neurodegenerative disorder is an age-related cognitive impairment.
[0714] In some implementations, the neurodegenerative disorder is a disorder of recurrent hypersomnia.
[0715] In some implementations, the disorder of recurrent hypersomnia is Clay syndrome, inappropriate sleep timing (e.g., delayed or advanced sleep phase disorder), shift work disorder, or jet lag disorder.
[0716] In some implementations, the disease or disorder is a symptom of a rare genetic disorder.
[0717] In some implementations, the symptom of the rare genetic disorder is abnormal daytime sleepiness.
[0718] In some implementations, the symptom of the rare genetic disorder is excessive daytime sleepiness.
[0719] In some implementations, the symptoms of the rare genetic disorder are the REM sleep initiation stage.
[0720] In some implementations, the symptoms of the rare genetic disorder are characterized by sudden collapse-like symptoms.
[0721] In some implementations, the rare genetic disorder is ADCA-DN, Kohl's syndrome, Möbius syndrome, Norrie disease, Niemann-Pick disease type C, or Prad-Willi syndrome.
[0722] In some implementations, the disease or disorder is a mental health disorder.
[0723] In some implementations, the mental health disorder is attention deficit hyperactivity disorder (ADHD).
[0724] In some implementations, the mental health disorder is attention deficit disorder.
[0725] In some implementations, the disease or disorder is metabolic syndrome.
[0726] In some implementations, the metabolic syndrome is obesity.
[0727] In some implementations, the disease or disorder is osteoporosis.
[0728] In some implementations, the disease or disorder is heart failure.
[0729] In some implementations, the disease or disorder is coma.
[0730] In some implementations, the disease or disorder is anesthesia recovery.
[0731] In some implementations, the disease or disorder is an anesthesia recovery complication.
[0732] In some implementations, the disease or disorder is narcolepsy, excessive sleep disorder, neurodegenerative disorder, neurological disorder, symptoms of rare genetic disorders, mental disorder, psychological disorder, circadian rhythm disorder, metabolic syndrome, osteoporosis, heart failure, coma, or complications of anesthesia recovery.
[0733] In some implementations, the disease or disorder is narcolepsy, idiopathic hypersomnia, or sleep apnea.
[0734] Application route The compounds disclosed herein, or their pharmaceutically acceptable salts, may be administered alone as a sole therapy, or may be administered in combination with one or more other substances and / or treatments. Such combination therapy may be achieved by administering the individual components of the treatment simultaneously, sequentially, or separately.
[0735] For example, the efficacy of treatment can be enhanced by administering an adjuvant (i.e., the adjuvant itself may have only minimal therapeutic benefit, but when combined with another therapeutic agent, the overall therapeutic benefit to the individual is enhanced). Alternatively, by way of example only, the benefit experienced by an individual can be increased by administering a compound of formula (I) together with another therapeutic agent (which also includes a treatment regimen) that also has therapeutic benefits.
[0736] When the compounds of this disclosure are used in combination with other therapeutic agents, the compounds of this disclosure do not need to be administered via the same route as the other therapeutic agents, and can be administered via different routes due to their different physical and chemical characteristics. For example, the compounds of this disclosure can be administered orally to produce and maintain a good blood level, while other therapeutic agents can be administered intravenously. Initial administration can be performed according to established protocols known in the art, and then, based on observed effects, a skilled clinician can modify the dosage, administration mode, and frequency of administration.
[0737] The specific choice of other therapeutic agents will depend on the attending physician's diagnosis and their assessment of the individual's condition, as well as the appropriate treatment plan. According to this aspect of the disclosure, combinations are provided for treating diseases involving orexin activity, said combinations comprising compounds of the disclosure as defined above or pharmaceutically acceptable salts thereof, and another suitable pharmaceutical agent.
[0738] According to another aspect of this disclosure, a pharmaceutical composition is provided comprising a compound of this disclosure or a pharmaceutically acceptable salt thereof, and a suitable, pharmaceutically acceptable diluent or carrier.
[0739] In addition to their use in therapeutics, compounds of formula (I) and their pharmaceutically acceptable salts can also be used as pharmacological tools in the development and standardization of in vitro and in vivo testing systems to evaluate the modulatory effects of orexin-2 receptor activity in experimental animals such as dogs, rabbits, monkeys, miniature pigs, rats, and mice, as part of the search for new therapeutics.
[0740] In any of the pharmaceutical compositions, processes, methods, uses, pharmaceuticals, and preparation characteristics described in this disclosure, any alternative embodiments of the macromolecules of this disclosure described herein are also applicable.
[0741] The compounds of this disclosure or pharmaceutical compositions comprising these compounds may be administered to a subject via any convenient route of administration, whether systemic / peripheral or local (i.e., at the desired site of action).
[0742] Routes of administration include, but are not limited to, oral (e.g., by ingestion); sublingual; sublingual; transdermal (e.g., by patches, plasters, etc.); transmucosal (e.g., by patches, plasters, etc.); intranasal (e.g., by nasal sprays or powders); ocular (e.g., by eye drops); pulmonary (e.g., by inhalation or blowing therapy, using, for example, via aerosols, such as through the mouth or nose); rectal (e.g., by suppositories or enemas); vaginal (e.g., by pessaries); parenteral, such as by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, intracardiac, intrasheath, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subepidermal, intra-articular, subarachnoid, and intrasternal; and implantation via a reservoir or pool, such as subcutaneous or intramuscular.
[0743] Exemplary Implementation Exemplary Implementation Scheme No. 1 Compounds of formula (I'): (I'); Or its pharmaceutically acceptable salt, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl-、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; n is an integer in the range of 0 to 3; R a and R b Each of the following is independently H, halogen, -CN, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, wherein the -O(C1-C6 alkyl), -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally influenced by one or more R S Replace; or R a and R b Together with the atoms they are attached to, they form a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group, wherein the C3-C7 cyclic hydrocarbon group or the 3- to 7-membered heterocyclic hydrocarbon group is optionally surrounded by one or more R S replace; Each R SIt is independently a halogen, -CN, -OH, -O (C1-C6 alkyl), -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C1-C6 haloalkyl; Z is either -O- or -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -OH, -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -SH, -S (C1-C6 alkyl), -S (C6-C 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 -NH (3- to 7-membered heterocyclic hydrocarbon group), wherein -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -S (C1-C6 alkyl), -S (C6-C6 alkyl)2, -NH (C1-C6 alkyl)2, -NH ... 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace; Each R 1SIndependently, it is an oxo, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -S(C1-C6 alkyl), -SO2(C1-C6 alkyl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C7 cycloalkyl, or 3- to 7-membered heterocyclic alkyl group; Ar1 is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A1 replace; Each R A1 Independently, it is Ar2, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T either does not exist or is Ar2; Each Ar2 is independently C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 Replace; and Each R A2 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0744] Exemplary Implementation Scheme No. 2 Compounds of formula (I): (I); Or its pharmaceutically acceptable salt, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; n is an integer in the range of 0 to 3; Z is either -O- or -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -OH, -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -SH, -S (C1-C6 alkyl), -S (C6-C 10aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 -NH (3- to 7-membered heterocyclic hydrocarbon group), wherein -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -S (C1-C6 alkyl), -S (C6-C6 alkyl)2, -NH (C1-C6 alkyl)2, -NH ... 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace; Each R 1S Independently, it is an oxo, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -S(C1-C6 alkyl), -SO2(C1-C6 alkyl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C7 cycloalkyl, or 3- to 7-membered heterocyclic alkyl group; Ar1 is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A1 replace; Each R A1Independently, it is Ar2, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T either does not exist or is Ar2; Each Ar2 is independently C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 Replace; and Each R A2 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0745] Exemplary Implementation Scheme No. 3 The compound of any of the above exemplary embodiments, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl-, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; n is an integer in the range of 0 to 3; Z is either -O- or -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon, -NH-(C3-C 10 -NH-(3- to 7-membered heterocyclic hydrocarbon group) or -NH-(3- to 7-membered heterocyclic hydrocarbon group), wherein -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon group, -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace; Each R 1S It is independently a halogen, -CN, -OH, or C1-C6 alkoxy group; Ar1 is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A1 replace; Each R A1 Independently, it is Ar2, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T either does not exist or is Ar2; Each Ar2 is independently C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 Replace; and Each R A2 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0746] Exemplary Implementation Scheme No. 4 The compound of any of the above exemplary embodiments, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)- or C1-C6 alkyl; L is absent or is a C1-C6 alkyl group; Y is -O- or C1-C6 alkyl; n is an integer in the range of 0 to 3; Z is -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is a C1-C6 alkyl group; Ar1 is a C6-C that is optionally replaced by one or more Ar2. 10 Aryl; T either does not exist or is Ar2; and Each Ar2 is independently C6-C 10 Aryl.
[0747] Exemplary Implementation Scheme No. 5 The compound of any of the above exemplary embodiments, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)- or C1-C6 alkyl; L is absent or is a C1-C6 alkyl group; Y is -O- or C1-C6 alkyl; n is an integer in the range of 0 to 3; Z is -NRZ -; where R Z It is an H or C1-C6 alkyl group; R1 is a C1-C6 alkyl group; Ar1 is C6-C 10 Aryl; T is C6-C 10 Aryl.
[0748] Exemplary Implementation Scheme No. 6 The compound of any of the above exemplary embodiments, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)- or C1-C6 alkyl; L is absent or is a C1-C6 alkyl group; Y is -O- or C1-C6 alkyl; n is an integer in the range of 0 to 3; Z is -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is a C1-C6 alkyl group; Ar1 is optionally construed by one or more C6-C 10 Aryl-substituted C6-C 10 Aryl; and T does not exist.
[0749] Exemplary Implementation Scheme No. 7 The compound of exemplary embodiment 1, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)- or C1-C6 alkyl; L is absent or is a C1-C6 alkyl group; Y is -O- or C1-C6 alkyl; n is 2; Z is -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon, -NH-(C3-C 10 -NH-(3- to 7-membered heterocyclic hydrocarbon group), wherein -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon group, -NH-(C3-C6 alkyl)2, -NH-(C1 ... 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) is surrounded by one or more R 1S replace; Each R1S Independently, it is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -S(C1-C6 alkyl), -SO2(C1-C6 alkyl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C7 cycloalkyl or 3- to 7-membered heterocyclic alkyl group; Ar1 is optionally defined by one or more R A1 Replacement C6-C 10 Aryl; Each R A1 Independently, it is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T is Ar2; Ar2 is optionally defined by one or more R A2 Replacement C6-C 10 Aryl; and Each R A2 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0750] Exemplary Implementation Scheme No. 8 The compound of any of the above exemplary embodiments, wherein X is -O-.
[0751] Exemplary Implementation Scheme No. 9 The compound of any of the above exemplary embodiments, wherein X is -NH- or -N(C1-C6 alkyl)-, wherein the -N(C1-C6 alkyl)- is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0752] Exemplary Implementation Scheme No. 10 The compound of any of the above exemplary embodiments, wherein X is -NH-.
[0753] Exemplary Implementation Scheme No. 11 The compound of any of the above exemplary embodiments, wherein X is -N(C1-C6 alkyl)-.
[0754] Exemplary Implementation Scheme No. 12 The compound of any of the above exemplary embodiments, wherein X is -N(CH3)-.
[0755] Exemplary Implementation Scheme No. 13 The compound of any of the above exemplary embodiments, wherein X is a -N (C1-C6 alkyl)- substituted with one or more halogens or -OH.
[0756] Exemplary Implementation Scheme No. 14 The compound of any of the above exemplary embodiments, wherein X is a -N (C1-C6 alkyl)- substituted with one to three F and one -OH.
[0757] Exemplary Implementation Scheme No. 15 The compound in any of the above exemplary embodiments, wherein X is a C1-C6 alkyl, C3-C8 cyclic hydrocarbon, or C6-C6 cyclic hydrocarbon. 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0758] Exemplary Implementation Scheme No. 16 The compound of any of the above exemplary embodiments, wherein X is a C1-C6 alkyl group optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0759] Exemplary Implementation Scheme No. 17 The compound of any of the above exemplary embodiments, wherein X is a 3- to 8-membered heterocyclic hydrocarbon group optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0760] Exemplary Implementation Scheme No. 18 The compound of any of the above exemplary embodiments, wherein X is an azacyclobutyl group optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0761] Exemplary Implementation Scheme No. 19 The compound of any of the above exemplary embodiments, wherein X is or , wherein or Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0762] Exemplary Implementation Number 20 The compound of any of the above exemplary embodiments, wherein X is a azircyclic butyl group.
[0763] Exemplary Implementation Scheme No. 21 The compound of any of the above exemplary embodiments, wherein X is or .
[0764] Exemplary Implementation Number 22 The compound of any of the above exemplary embodiments, wherein L is absent.
[0765] Exemplary Implementation Scheme No. 23 The compound in any of the above exemplary embodiments, wherein L is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0766] Exemplary Implementation Number 24The compound of any of the above exemplary embodiments, wherein L is -O-.
[0767] Exemplary Implementation Number 25 The compound of any of the above exemplary embodiments, wherein L is -NH- or -N(C1-C6 alkyl)-, wherein the -N(C1-C6 alkyl)- is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl)2 or -N(C1-C6 alkyl)2.
[0768] Exemplary Implementation Scheme No. 26 The compound in any of the above exemplary embodiments, wherein L is a C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl - wherein the C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0769] Exemplary Implementation Scheme No. 27 The compound of any of the above exemplary embodiments, wherein L is a C1-C6 alkyl or C2-C6 alkenyl, wherein the C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0770] Exemplary Implementation Scheme No. 28The compound in any of the above exemplary embodiments, wherein L is -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl - wherein the -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0771] Exemplary Implementation Scheme No. 29 The compound in any of the above exemplary embodiments, wherein L is -((C1-C6 alkyl)-O). nl -or-(O-(C1-C6 alkyl)) nl - wherein the -((C1-C6 alkyl)-O) nl -or-(O-(C1-C6 alkyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0772] Exemplary Implementation Scheme No. 30 The compound in any of the above exemplary embodiments, wherein L is -((C1-C6 alkyl)-NH) nl -or-(NH-(C1-C6 alkyl)) nl - wherein -((C1-C6 alkyl)-NH) nl -or-(NH-(C1-C6 alkyl)) nl-Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0773] Exemplary Implementation Scheme No. 31 The compound of any of the above exemplary embodiments, wherein nl is an integer in the range of 1 to 3.
[0774] Exemplary Implementation Scheme No. 32 The compound of any of the above exemplary embodiments, wherein nl is 1.
[0775] Exemplary Implementation Scheme No. 33 The compound of any of the above exemplary embodiments, wherein nl is 2.
[0776] Exemplary Implementation Scheme No. 34 The compound of any of the above exemplary embodiments, wherein nl is 3.
[0777] Exemplary Implementation Number 35 The compound of any of the above exemplary embodiments, wherein Y is -O-.
[0778] Exemplary Implementation Scheme No. 36 The compound of any of the above exemplary embodiments, wherein Y is -NH- or -N(C1-C6 alkyl)-, wherein the -N(C1-C6 alkyl)- is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0779] Exemplary Implementation Number 37 The compound of any of the above exemplary embodiments, wherein Y is -NH-.
[0780] Exemplary Implementation Scheme No. 38 The compounds in any of the above exemplary embodiments, wherein -N(C1-C6 alkyl)- is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0781] Exemplary Implementation Scheme No. 39 The compound of any of the above exemplary embodiments, wherein Y is a C1-C6 alkyl or C2-C6 alkenyl, wherein the C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0782] Exemplary Implementation Number 40The compound of any of the above exemplary embodiments, wherein Y is a C1-C6 alkyl group optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0783] Exemplary Implementation Scheme No. 41 The compound of any of the above exemplary embodiments, wherein Y is a C2-C6 alkenyl group optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0784] Exemplary Implementation Scheme No. 42 The compounds in any of the above exemplary embodiments, wherein at most one of X and L is -O-, -NH-, or optionally substituted -N (C1-C6 alkyl)-.
[0785] Exemplary Implementation Scheme No. 43 The compounds in any of the above exemplary embodiments, wherein at most one of L and Y is -O-, -NH-, or optionally substituted -N (C1-C6 alkyl)-.
[0786] Exemplary Implementation Number 44 The compounds in any of the above exemplary embodiments, wherein at most one of X and Y is -O-, -NH-, or optionally substituted -N (C1-C6 alkyl)-.
[0787] Exemplary Implementation Number 45 The compounds in any of the above exemplary embodiments, wherein at most two of X, L and Y are -O-, -NH- or optionally substituted -N (C1-C6 alkyl)-.
[0788] Exemplary Implementation Scheme No. 46 The compound of any of the above exemplary embodiments, wherein at most one of X, L and Y is -O-, -NH- or optionally substituted -N (C1-C6 alkyl)-.
[0789] Exemplary Implementation Number 47 In any of the above exemplary embodiments, when X is -O-, -NH-, or optionally substituted -N(C1-C6 alkyl)- and Y is -O-, -NH-, or optionally substituted -N(C1-C6 alkyl)-, then L is not absent, -O-, -NH-, or optionally substituted -N(C1-C6 alkyl)-.
[0790] Exemplary Implementation Scheme No. 48 The compound of any of the above exemplary embodiments, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl - wherein the C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH (C1-C6 alkyl) or -N (C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; and Y is a C1-C6 alkyl or C2-C6 alkenyl group, wherein the C1-C6 alkyl or C2-C6 alkenyl group is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0791] Exemplary Implementation Scheme No. 49The compound of any of the above exemplary embodiments, wherein: X is a C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, or C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH (C1-C6 alkyl) or -N (C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; and Y is a C1-C6 alkyl or C2-C6 alkenyl group, wherein the C1-C6 alkyl or C2-C6 alkenyl group is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0792] Exemplary Implementation Scheme No. 50 The compound of any of the above exemplary embodiments, wherein: X is a C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, or C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl - wherein the C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH (C1-C6 alkyl) or -N (C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; and Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl, or C1-C6 alkoxy.
[0793] Exemplary Implementation Scheme No. 51 In any of the above exemplary embodiments, X is -O-, -NH-, -N(C1-C6 alkyl)- or C1-C6 alkyl; L is absent or is C1-C6 alkyl; and Y is -O- or C1-C6 alkyl.
[0794] Exemplary Implementation Scheme No. 52 In any of the above exemplary embodiments, X is -O-, -NH-, or -N(C1-C6 alkyl)-; L is C1-C6 alkyl; and Y is -O-.
[0795] Exemplary Implementation Scheme No. 53 In any of the above exemplary embodiments, X is a C1-C6 alkyl group; L is absent; and Y is a C1-C6 alkyl group.
[0796] Exemplary Implementation Number 54 The compound of any of the above exemplary embodiments, where n is 1.
[0797] Exemplary Implementation Number 55 The compound of any of the above exemplary embodiments, wherein n is 2.
[0798] Exemplary Implementation Scheme No. 56 The compound of any of the above exemplary embodiments, wherein R a and R b Each is independently H or halogen; or R a and R b Together with the atoms they are attached to, they form a group optionally bounded by one or more R atoms. S Substituted C3-C7 cyclic hydrocarbon groups.
[0799] Exemplary Implementation Number 57 The compound of any of the above exemplary embodiments, wherein R a and R b One of them is H, and R a and R b One of them is halogen.
[0800] Exemplary Implementation Number 58 The compound of any of the above exemplary embodiments, wherein R a and R bTogether with the atoms they are attached to, they form cyclopropyl groups.
[0801] Exemplary Implementation Scheme No. 59 The compound of any of the above exemplary embodiments, wherein Z is -O-.
[0802] Exemplary Implementation Scheme No. 60 The compound of any of the above exemplary embodiments, wherein Z is -NR Z -
[0803] Exemplary Implementation Scheme No. 61 The compound of any of the above exemplary embodiments, wherein Z is -NH-.
[0804] Exemplary Implementation Scheme No. 62 The compound in any of the above exemplary embodiments, wherein R1 is -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon, -NH-(C3-C 10 -NH-(3- to 7-membered heterocyclic hydrocarbon group) or -NH-(3- to 7-membered heterocyclic hydrocarbon group), wherein -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon group, -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace.
[0805] Exemplary Implementation Scheme No. 63 The compound in any of the above exemplary embodiments, wherein R1 is -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon, -NH-(C3-C 10 -NH-(3- to 7-membered heterocyclic hydrocarbon group) or -NH-(3- to 7-membered heterocyclic hydrocarbon group), wherein -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon group, -NH-(C3-C 10 The cyclic hydrocarbon group or -NH- (3- to 7-membered heterocyclic hydrocarbon group) is optionally substituted with one or more halogens, -CN, -OH or C1-C6 alkoxy groups.
[0806] Exemplary Implementation Scheme No. 64 The compound of any of the above exemplary embodiments, wherein R1 is -OH.
[0807] Exemplary Implementation Number 65The compound in any of the above exemplary embodiments, wherein R1 is -NH2, -NH(C1-C6 alkyl)2, or -N(C1-C6 alkyl)2, wherein the -NH(C1-C6 alkyl)2 or -N(C1-C6 alkyl)2 is optionally replaced by one or more R 1S replace.
[0808] Exemplary Implementation Scheme No. 66 The compound in any of the above exemplary embodiments, wherein R1 is -SH, -S (C1-C6 alkyl) or -S (C6-C6 alkyl). 10 aryl), wherein the -S(C1-C6 alkyl) or -S(C6-C 10 Aryl) optionally by one or more R 1S replace.
[0809] Exemplary Implementation Number 67 The compound in any of the above exemplary embodiments, wherein R1 is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, or C6-C6 alkyl group. 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon or 3- to 7-membered heterocyclic hydrocarbon, wherein the C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon or 3- to 7-membered heterocyclic hydrocarbon, optionally bounded by one or more R 1S replace.
[0810] Exemplary Implementation Scheme No. 68 The compound of any of the above exemplary embodiments, wherein R1 is optionally mixed with one or more R... 1S Substituted C1-C6 alkyl groups.
[0811] Exemplary Implementation Scheme No. 69 The compound of any of the above exemplary embodiments, wherein R1 is a C1-C6 alkyl group.
[0812] Exemplary Implementation Number 70 The compound of any of the above exemplary embodiments, wherein R1 is methyl.
[0813] Exemplary Implementation Scheme No. 71 The compound of any of the above exemplary embodiments, wherein R1 is an ethyl group.
[0814] Exemplary Implementation Scheme No. 72 The compound of any of the above exemplary embodiments, wherein R1 is optionally mixed with one or more R... 1S Substituted C3-C7 cyclic hydrocarbon groups.
[0815] Exemplary Implementation Number 73 The compound of any of the above exemplary embodiments, wherein R1 is optionally mixed with one or more R... 1S Substituted cyclopropyl group.
[0816] Exemplary Implementation Number 74 The compound of any of the above exemplary embodiments, wherein R1 is a cyclopropyl group optionally substituted with one or more F groups.
[0817] Exemplary Implementation Number 75 The compound of any of the above exemplary embodiments, wherein R1 is -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -O-(3- to 7-membered heterocyclic hydrocarbon group), wherein the -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 (cyclic hydrocarbon group) or -O-(3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace.
[0818] Exemplary Implementation Number 76 The compound of any of the above exemplary embodiments, wherein R1 is -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 (C6-C) or -NH- (3- to 7-membered heterocyclic hydrocarbon group), wherein the NH- (C6-C) 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace.
[0819] Exemplary Implementation Number 77 The compound of any of the above exemplary embodiments, wherein at least one R 1S It is a halogen, -CN, -OH or C1-C6 alkoxy group.
[0820] Exemplary Implementation Number 78 The compound of any of the above exemplary embodiments, wherein at least one R 1S It is halogen.
[0821] Exemplary Implementation Scheme No. 79 The compound of any of the above exemplary embodiments, wherein at least one R 1S It is a C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 alkoxy group.
[0822] Exemplary Implementation Scheme No. 80 The compound of any of the above exemplary embodiments, wherein at least one R 1S It is a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group.
[0823] Exemplary Implementation Scheme No. 81 The compound of any of the above exemplary embodiments, wherein Ar1 is optionally mixed with one or more R A1 Replacement C6-C 10 Aryl.
[0824] Exemplary Implementation Number 82 The compound of any of the above exemplary embodiments, wherein Ar1 is optionally mixed with one or more R A1 Substituted phenyl groups.
[0825] Exemplary Implementation Scheme No. 83 The compound of any of the above exemplary embodiments, wherein Ar1 is .
[0826] Exemplary Implementation Scheme No. 84 The compound of any of the above exemplary embodiments, wherein Ar1 is .
[0827] Exemplary Implementation Number 85 The compound of any of the above exemplary embodiments, wherein Ar1 is optionally mixed with one or more R A1 Substituted 5- to 10-membered heteroaryl groups.
[0828] Exemplary Implementation Scheme No. 86 The compound of any of the above exemplary embodiments, wherein Ar1 is optionally mixed with one or more R A1 Substituted pyridinyl or thiazolyl groups.
[0829] Exemplary Implementation Number 87 The compound of any of the above exemplary embodiments, wherein Ar1 is optionally mixed with one or more R A1 Substituted pyridinyl group.
[0830] Exemplary Implementation Number 88 The compound of any of the above exemplary embodiments, wherein Ar1 is .
[0831] Exemplary Implementation Scheme No. 89 The compound of any of the above exemplary embodiments, wherein at least one R A1 It is Ar2.
[0832] Exemplary Implementation Scheme No. 90 The compound of any of the above exemplary embodiments, wherein at least one R A1 It is C6-C 10aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 replace.
[0833] Exemplary Implementation Scheme No. 91 The compound of any of the above exemplary embodiments, wherein at least one R A1 It is optionally controlled by one or more R A2 Replacement C6-C 10 Aryl.
[0834] Exemplary Implementation Scheme No. 92 The compound of any of the above exemplary embodiments, wherein at least one R A1 It is optionally controlled by one or more R A2 Substituted phenyl groups.
[0835] Exemplary Implementation Scheme No. 93 The compound of any of the above exemplary embodiments, wherein at least one R A1 It is a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0836] Exemplary Implementation Scheme No. 94 The compound of any of the above exemplary embodiments, wherein at least one R A1 It is halogen.
[0837] Exemplary Implementation Number 95 The compound of any of the above exemplary embodiments, wherein at least one R A1 It is F.
[0838] Exemplary Implementation Scheme No. 96 The compound of any of the above exemplary embodiments, wherein T is absent.
[0839] Exemplary Implementation Number 97 The compound of any of the above exemplary embodiments, wherein T is Ar2.
[0840] Exemplary Implementation Scheme No. 98 The compound of any of the above exemplary embodiments, wherein T is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 replace.
[0841] Exemplary Implementation Number 99The compound of any of the above exemplary embodiments, wherein T is optionally mixed with one or more R A2 Replacement C6-C 10 Aryl.
[0842] Exemplary Implementation Scheme No. 100 The compound of any of the above exemplary embodiments, wherein T is optionally mixed with one or more R A2 Substituted phenyl groups.
[0843] Exemplary Implementation Scheme No. 101 The compound of any of the above exemplary embodiments, wherein T is .
[0844] Exemplary Implementation Scheme No. 102 The compound of any of the above exemplary embodiments, wherein T is optionally mixed with one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0845] Exemplary Implementation Scheme No. 103 The compound of any of the above exemplary embodiments, wherein at least one R A1 It is Ar2, and T does not exist.
[0846] Exemplary Implementation Scheme No. 104 The compound of any of the above exemplary embodiments, wherein Ar1 is And T does not exist.
[0847] Exemplary Implementation Scheme No. 105 The compounds in any of the above exemplary embodiments, wherein each R A1 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; and T is Ar2.
[0848] Exemplary Implementation Scheme No. 106 The compound of any of the above exemplary embodiments, wherein Ar1 is And T is Ar2.
[0849] Exemplary Implementation Scheme No. 107 The compound of any of the above exemplary embodiments, wherein Ar1 is And T is Ar2.
[0850] Exemplary Implementation Scheme No. 108 The compounds in any of the above exemplary embodiments, wherein each R A1It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; and T is Ar2.
[0851] Exemplary Implementation Scheme No. 109 The compound of any of the above exemplary embodiments, wherein at least one Ar2 is optionally mixed with one or more R A2 Replacement C6-C 10 Aryl.
[0852] Exemplary Implementation Scheme No. 110 The compound of any of the above exemplary embodiments, wherein at least one Ar2 is optionally mixed with one or more R A2 Substituted phenyl groups.
[0853] Exemplary Implementation Scheme No. 111 The compound of any of the above exemplary embodiments, wherein at least one Ar2 is optionally mixed with one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0854] Exemplary Implementation Scheme No. 112 The compound of any of the above exemplary embodiments, wherein at least one R A2 It is halogen.
[0855] Exemplary Implementation Scheme No. 113 The compound of any of the above exemplary embodiments, wherein at least one R A2 It is F.
[0856] Exemplary Implementation Scheme No. 114 The compound of any of the above exemplary embodiments, wherein at least one R A2 It is a C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl, or C2-C6 alkynyl.
[0857] Exemplary Implementation Scheme No. 115The compound of any of the above exemplary embodiments, wherein the compound has the formula (I'-a), (I'-b), (IA'), (IA'-a), (IA'-b), (IB'), (IB'-a), (IB'-b), (II'), (II'-a), (II'-b), (IIA'), (IIA'-a), (IIA'-b), (IIB'), (IIB'-a), (IIB'-b), (IIIA'), (IIIA'-a), (IIIA'-b), (IIIB'), (IIIB'-a) or (IIIB'-b), (IVA'), (IVA'-a), (IVA'-b), (VA'), (VA'-a) or (VA'-b) or a pharmaceutically acceptable salt thereof, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0858] Exemplary Implementation Scheme No. 116 The compound of any of the above exemplary embodiments, wherein the compound has the formula (Ia), (Ib), (IA), (IA-a), (IA-b), (IB), (IB-a), (IB-b), (II), (II-a), (II-b), (IIA), (IIA-a), (IIA-b), (IIB), (IIB-a), (IIB-b), (IIIA), (IIIA-a), (IIIA-b), (IIIB), (IIIB-a) or (IIIB-b), (IVA), (IVA-a), (IVA-b), (VA), (VA-a) or (VA-b) or a pharmaceutically acceptable salt thereof, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0859] Exemplary Implementation Number 117 The compound of any of the above exemplary embodiments, wherein: R1 is -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon, -NH-(C3-C 10 -NH-(3- to 7-membered heterocyclic hydrocarbon group), wherein -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, 5- to 10-membered heteroaryl, 3- to 7-membered heterocyclic hydrocarbon group, -NH-(C3 ... -NH-(C1-C6 alkyl)2, 5- to 10-membered heteroaryl, -NH-(C1-C6 alkyl)2, 5- to 10-membered heteroaryl, -NH-(C1-C6 alkyl)2, 5- 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S Substitution and C1-C6 alkyl groups are formed by one or more R 1S replace; Each R 1S It is independently a halogen or a C1-C6 alkyl group; Each R A1 It is a halogen on its own; Each R A2 Halogens are independent n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0860] Exemplary Implementation Number 118 The compounds in any of the above exemplary embodiments, wherein the compounds are selected from the compounds described in Table A1 and their pharmaceutically acceptable salts.
[0861] Exemplary Implementation Scheme No. 119 The compounds in any of the above exemplary embodiments, wherein the compounds are selected from compound numbers A1-6, A1-6, A1-10, A1-15, A1-42, A1-58, A1-59, A1-60, A1-61, A1-63 to A1-102, and pharmaceutically acceptable salts thereof.
[0862] Exemplary Implementation Scheme No. 120 The compounds in any of the above exemplary embodiments, wherein the compounds are selected from the compounds described in Table A2 and their pharmaceutically acceptable salts.
[0863] Exemplary Implementation Scheme No. 121 The compounds in any of the above exemplary embodiments, wherein the compounds are selected from the compounds described in Table B1 and their pharmaceutically acceptable salts.
[0864] Exemplary Implementation Scheme No. 122 The compounds in any of the exemplary embodiments described above, wherein the compounds are selected from the compounds described in Table B2 and their pharmaceutically acceptable salts.
[0865] Exemplary Implementation Scheme No. 123 Compounds that can be obtained or are obtained by the methods described herein; optionally, the methods include one or more steps described in schemes 1-5.
[0866] Exemplary Implementation Scheme No. 124 A pharmaceutical composition comprising a compound of any one of the exemplary embodiments described above or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
[0867] Exemplary Implementation Number 125 The pharmaceutical composition of any of the above exemplary embodiments, wherein the compound is selected from the compounds described in Tables A1, A2, B1 and B2.
[0868] Exemplary Implementation Scheme No. 126A method for modulating orexin-2 receptor activity includes contacting cells with an effective amount of a compound from any of the above exemplary embodiments; optionally, the activity is in vitro or in vivo.
[0869] Exemplary Implementation Number 127 A method for treating or preventing a disease or disorder in a subject in need, comprising administering to the subject a therapeutically effective amount of a compound or pharmaceutical composition of any of the above exemplary embodiments.
[0870] Exemplary Implementation Number 128 The compound or pharmaceutical composition of any of the above exemplary embodiments is used to modulate orexin-2 receptor activity; optionally, the activity is in vitro or in vivo.
[0871] Exemplary Implementation Scheme No. 129 The compound or pharmaceutical composition of any of the above exemplary embodiments is used to treat or prevent a disease or disorder.
[0872] Exemplary Implementation Scheme No. 130 Use of the compound of any of the above exemplary embodiments in the preparation of a medicament for modulating orexin-2 receptor activity; optionally, the activity is in vitro or in vivo.
[0873] Exemplary Implementation Scheme No. 131 The use of any of the compounds in the above exemplary embodiments in the preparation of a medicament for treating or preventing a disease or disorder.
[0874] Exemplary Implementation Scheme No. 132 The methods, compounds, pharmaceutical compositions, or uses of any of the above exemplary embodiments, wherein the disease or disorder is related to the orexin-2 receptor.
[0875] Exemplary Implementation Scheme No. 133 The method, compound, pharmaceutical composition, or use of any of the above exemplary embodiments, wherein the disease or disorder is a neurodegenerative disorder, neurological disorder, symptoms of a rare genetic disorder, mental disorder, psychological disorder, circadian rhythm disorder, metabolic syndrome, osteoporosis, heart failure, coma, or complications of anesthesia recovery.
[0876] Exemplary Implementation Scheme No. 134 The method, compound, pharmaceutical composition, or use of any of the above exemplary embodiments, wherein the disease or disorder is narcolepsy, idiopathic hypersomnia, sleep apnea, or insomnia.
[0877] This invention provides, but is not limited to, the following embodiments: 1. Compounds of formula (I'): (I'); Or its pharmaceutically acceptable salt, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; n is an integer in the range of 0 to 3; R a and R b Each of the following is independently H, halogen, -CN, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, wherein the -O(C1-C6 alkyl), -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally influenced by one or more R S Replace; or R a and R b Together with the atoms they are attached to, they form a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group, wherein the C3-C7 cyclic hydrocarbon group or the 3- to 7-membered heterocyclic hydrocarbon group is optionally surrounded by one or more R S replace; Each R S It is independently a halogen, -CN, -OH, -O (C1-C6 alkyl), -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C1-C6 haloalkyl; Z is either -O- or -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -OH, -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -SH, -S (C1-C6 alkyl), -S (C6-C 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 -NH (3- to 7-membered heterocyclic hydrocarbon group), wherein -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -S (C1-C6 alkyl), -S (C6-C6 alkyl)2, -NH (C1-C6 alkyl)2, -NH ... 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -cyclic hydrocarbon group), -O-(3- to 7-membered heterocyclic hydrocarbon group), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace; Each R 1S Independently, it is an oxo, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -S(C1-C6 alkyl), -SO2(C1-C6 alkyl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C7 cycloalkyl, or 3- to 7-membered heterocyclic alkyl group; Ar1 is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A1 replace; Each R A1 Independently, it is Ar2, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T either does not exist or is Ar2; Each Ar2 is independently C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 Replace; and Each R A2It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
[0878] 2. The compound of embodiment 1, wherein the compound has formula (I): (I); Or its pharmaceutically acceptable salt.
[0879] 3. The compound described in any of the foregoing embodiments, wherein X is -O-.
[0880] 4. The compound of any of the foregoing embodiments, wherein X is -NH- or -N(C1-C6 alkyl)-, wherein the -N(C1-C6 alkyl)- is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0881] 5. The compound described in any of the foregoing embodiments, wherein X is -NH- or -N(CH3)-.
[0882] 6. The compound described in any of the foregoing embodiments, wherein X is a C1-C6 alkyl group optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0883] 7. The compound described in any of the foregoing embodiments, wherein X is an azacyclobutyl group optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy.
[0884] 8. The compound described in any of the foregoing embodiments, wherein L is absent.
[0885] 9. The compound described in any of the foregoing embodiments, wherein L is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl-、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0886] 10. The compound described in any of the foregoing embodiments, wherein L is -O-.
[0887] 11. The compound of any of the foregoing embodiments, wherein L is -NH- or -N(C1-C6 alkyl)-, wherein the -N(C1-C6 alkyl)- is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl)2 or -N(C1-C6 alkyl)2.
[0888] 12. The compound of any of the foregoing embodiments, wherein L is a C1-C6 alkyl or C2-C6 alkenyl, wherein the C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0889] 13. The compound described in any of the foregoing embodiments, wherein L is -((C1-C6 alkyl)-O). nl -or-(O-(C1-C6 alkyl)) nl - wherein the -((C1-C6 alkyl)-O) nl -or-(O-(C1-C6 alkyl)) nl-Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0890] 14. The compound described in any of the foregoing embodiments, wherein L is -((C1-C6 alkyl)-NH) nl -or-(NH-(C1-C6 alkyl)) nl - wherein -((C1-C6 alkyl)-NH) nl -or-(NH-(C1-C6 alkyl)) nl -Optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2.
[0891] 15. The compound described in any of the foregoing embodiments, wherein nl is an integer in the range of 1 to 3.
[0892] 16. The compound according to any of the foregoing embodiments, wherein Y is -O-.
[0893] 17. The compound described in any of the foregoing embodiments, wherein Y is -NH-.
[0894] 18. The compound described in any of the foregoing embodiments, wherein Y is a C1-C6 alkyl group optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy groups.
[0895] 19. The compound described in any of the foregoing embodiments, wherein n is 1.
[0896] 20. The compound described in any of the foregoing embodiments, wherein n is 2.
[0897] 21. The compound according to any of the foregoing embodiments, wherein R a and R b Each is independently H or halogen; or R a and R b Together with the atoms they are attached to, they form a group optionally bounded by one or more R atoms. S Substituted C3-C7 cyclic hydrocarbon groups.
[0898] 22. The compound according to any of the foregoing embodiments, wherein R a and R b One of them is H, and R a and R b One of them is halogen.
[0899] 23. The compound according to any of the foregoing embodiments, wherein R a and R b Together with the atoms they are attached to, they form cyclopropyl groups.
[0900] 24. The compound described in any of the foregoing embodiments, wherein Z is -O-.
[0901] 25. The compound described in any of the foregoing embodiments, wherein Z is -NH-.
[0902] 26. The compound according to any of the foregoing embodiments, wherein R1 is optionally reacted with one or more R 1S Substituted C1-C6 alkyl groups.
[0903] 27. The compound described in any of the foregoing embodiments, wherein R1 is methyl or ethyl.
[0904] 28. The compound according to any of the foregoing embodiments, wherein R1 is optionally reacted with one or more R... 1S Substituted C3-C7 cyclic hydrocarbon groups.
[0905] 29. The compound according to any of the foregoing embodiments, wherein R1 is optionally reacted with one or more R 1S Substituted cyclopropyl group.
[0906] 30. The compound according to any one of the foregoing embodiments, wherein at least one R 1S It is halogen.
[0907] 31. The compound according to any of the foregoing embodiments, wherein Ar1 is optionally reacted with one or more R A1 Replacement C6-C 10 Aryl.
[0908] 32. The compound according to any of the foregoing embodiments, wherein Ar1 is optionally reacted with one or more R A1 Substituted 5- to 10-membered heteroaryl groups.
[0909] 33. The compound according to any of the foregoing embodiments, wherein at least one R A1 It is Ar2.
[0910] 34. The compound according to any one of the foregoing embodiments, wherein at least one R A1 It is optionally controlled by one or more R A2 Replacement C6-C 10 Aryl.
[0911] 35. The compound according to any one of the foregoing embodiments, wherein at least one R A1 It is halogen.
[0912] 36. The compound described in any of the foregoing embodiments, wherein T is absent.
[0913] 37. The compound described in any of the foregoing embodiments, wherein T is Ar2.
[0914] 38. The compound according to any one of the foregoing embodiments, wherein at least one R A1 It is Ar2, and T does not exist.
[0915] 39. The compound according to any of the foregoing embodiments, wherein Ar1 is And T does not exist.
[0916] 40. The compound according to any of the foregoing embodiments, wherein Ar1 is And T is Ar2.
[0917] 41. The compound according to any of the foregoing embodiments, wherein Ar1 is And T is Ar2.
[0918] 42. The compound according to any of the foregoing embodiments, wherein at least one Ar2 is optionally reacted with one or more R A2 Replacement C6-C 10 Aryl.
[0919] 43. The compound according to any of the foregoing embodiments, wherein at least one Ar2 is optionally reacted with one or more R A2 Substituted 5- to 10-membered heteroaryl groups.
[0920] 44. The compound according to any of the foregoing embodiments, wherein at least one R A2 It is halogen.
[0921] 45. The compound according to any of the foregoing embodiments, wherein the compound has the formula (I'-a), (I'-b), (IA'), (IA'-a), (IA'-b), (IB'), (IB'-a), (IB'-b), (II'), (II'-a), (II'-b), (IIA'), (IIA'-a), (IIA'-b), (IIB'), (IIB'-a), (IIB'-b), (IIIA'), (IIIA'-a), (IIIA'-b), (IIIB'), (IIIB'-a) or (IIIB'-b), (IVA'), (IVA'-a), (IVA'-b), (VA'), (VA'-a) or (VA'-b): (I'-a) (I'-b) (IA') (IA'-a) (IA'-b) (IB') (IB'-a) (IB'-b) (II') (II'-a) (II'-b) (IIA'), (IIA'-a) (IIA'-b) (IIB'), (IIB'-a) (IIB'-b) (IIIA') (IIIA'-a) (IIIA'-b) (IIIB') (IIIB'-a) (IIIB'-b) (IVA') (IVA'-a) (IVA'-b) (VA') (VA'-a) or (VA'-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0922] 46. The compound according to any of the foregoing embodiments, wherein the compound has the formula (Ia), (Ib), (IA), (IA-a), (IA-b), (IB), (IB-a), (IB-b), (II), (II-a), (II-b), (IIA), (IIA-a), (IIA-b), (IIB), (IIB-a), (IIB-b), (IIIA), (IIIA-a), (IIIA-b), (IIIB), (IIIB-a) or (IIIB-b), (IVA), (IVA-a), (IVA-b), (VA), (VA-a) or (VA-b): (Ia) (Ib) (IA) (IA-a) (IA-b) (IB) (IB-a) (IB-b) (II) (II-a) (II-b) (IIA) (IIA-a) (IIA-b) (IIB) (IIB-a) (IIB-b) (IIIA) (IIIA-a) (IIIA-b) (IIIB) (IIIB-a) (IIIB-b) (IVA) (IVA-a) (IVA-b) (VA), (VA-a) or (VA-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
[0923] 47. The compound of any of the foregoing embodiments, wherein the compound is selected from the compounds described in Table A1 and their pharmaceutically acceptable salts.
[0924] 48. The compound of any of the foregoing embodiments, wherein the compound is selected from the compounds described in Table A2 and their pharmaceutically acceptable salts.
[0925] 49. The compound of any of the foregoing embodiments, wherein the compound is selected from the compounds described in Table B1 and their pharmaceutically acceptable salts.
[0926] 50. The compound of any of the foregoing embodiments, wherein the compound is selected from the compounds described in Table B2 and their pharmaceutically acceptable salts.
[0927] 51. Compounds that can be obtained or are obtained by the methods described herein; Optionally, the method includes one or more steps described in schemes 1-5.
[0928] 52. A pharmaceutical composition comprising the compound described in any of the foregoing embodiments or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
[0929] 53. The pharmaceutical composition according to any of the foregoing embodiments, wherein the compound is selected from the compounds described in Tables A1, A2, B1 and B2.
[0930] 54. A method for modulating orexin-2 receptor activity, comprising contacting cells with an effective amount of the compound described in any of the foregoing embodiments; optionally, the activity is in vitro or in vivo.
[0931] 55. A method for treating or preventing a disease or disorder in a subject in need, comprising administering to the subject a therapeutically effective amount of the compound or pharmaceutical composition described in any of the foregoing embodiments.
[0932] 56. The compound or pharmaceutical composition described in any of the foregoing embodiments, for regulating orexin-2 receptor activity; optionally, said activity is in vitro or in vivo.
[0933] 57. The compound or pharmaceutical composition described in any of the foregoing embodiments, for the treatment or prevention of disease or disorder.
[0934] 58. Use of the compound described in any of the foregoing embodiments in the preparation of a medicament for regulating or...
Claims
1. Compounds of formula (I'): (I’); Or its pharmaceutically acceptable salt, wherein: X is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 aryl, 3- to 8-membered heterocyclic hydrocarbon group or 5- to 10-membered heteroaryl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl, C3-C8 cyclic hydrocarbon group, C6-C 10 The aryl, 3- to 8-membered heterocyclic hydrocarbon or 5- to 10-membered heteroaryl group is optionally substituted by one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; L is absent, or it is either -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, or -((C1-C6 alkyl)-O). nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -, wherein -N(C1-C6 alkyl)-, C1-C6 alkyl, C2-C6 alkenyl, -((C1-C6 alkyl)-O) nl -、-(O-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-O) nl -、-(O-(C2-C6 alkenyl)) nl -、-((C1-C6 alkyl)-NH) nl -、-(NH-(C1-C6 alkyl)) nl -、-((C2-C6 alkenyl)-NH) nl -or-(NH-(C2-C6 alkenyl)) nl -Optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl) or -N(C1-C6 alkyl)2; and nl is an integer in the range of 1 to 6; Y is -O-, -NH-, -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl, wherein the -N(C1-C6 alkyl)-, C1-C6 alkyl or C2-C6 alkenyl is optionally substituted with one or more halogens, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 haloalkyl or C1-C6 alkoxy; n is an integer in the range of 0 to 3; R a and R b Each of the following is independently H, halogen, -CN, -OH, -O(C1-C6 alkyl), -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl, wherein the -O(C1-C6 alkyl), -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl is optionally influenced by one or more R S Replace; or R a and R b Together with the atoms they are attached to, they form a C3-C7 cyclic hydrocarbon group or a 3- to 7-membered heterocyclic hydrocarbon group, wherein the C3-C7 cyclic hydrocarbon group or the 3- to 7-membered heterocyclic hydrocarbon group is optionally surrounded by one or more R S replace; Each R S It is independently a halogen, -CN, -OH, -O (C1-C6 alkyl), -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl or C1-C6 haloalkyl; Z is either -O- or -NR Z -; where R Z It is an H or C1-C6 alkyl group; R1 is -OH, -NH2, -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -SH, -S (C1-C6 alkyl), -S (C6-C 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -O-(3- to 7-membered heterocyclic hydrocarbon groups), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 -NH (3- to 7-membered heterocyclic hydrocarbon group), wherein -NH (C1-C6 alkyl), -N (C1-C6 alkyl)2, -S (C1-C6 alkyl), -S (C6-C6 alkyl)2, -NH (C1-C6 alkyl)2, -NH ...1-C6 alkyl)2, -NH (C6-C6 alkyl 10 aryl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, C6-C 10 aryl, 5- to 10-membered heteroaryl, C3-C7 cyclic hydrocarbon group, 3- to 7-membered heterocyclic hydrocarbon group, -O-(C6-C 10 aryl), -O-(5- to 10-membered heteroaryl), -O-(C3-C 10 -O-(3- to 7-membered heterocyclic hydrocarbon groups), -NH-(C6-C 10 aryl), -NH-(5- to 10-membered heteroaryl), -NH-(C3-C 10 (cyclic hydrocarbon group) or -NH- (3- to 7-membered heterocyclic hydrocarbon group) optionally surrounded by one or more R 1S replace; Each R 1S Independently, it is an oxo, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, -S(C1-C6 alkyl), -SO2(C1-C6 alkyl), C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkoxy, C3-C7 cycloalkyl, or 3- to 7-membered heterocyclic alkyl group; Ar1 is C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A1 replace; Each R A1 Independently, it is Ar2, halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl; T does not exist; Each Ar2 is independently C6-C 10 aryl or 5- to 10-membered heteroaryl, wherein the C6-C 10 aryl or 5- to 10-membered heteroaryl groups are optionally bounded by one or more R groups. A2 Replace; and Each R A2 It is independently a halogen, -CN, -OH, -NH2, -NH(C1-C6 alkyl), -N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C2-C6 alkenyl or C2-C6 alkynyl.
2. The compound of claim 1, wherein the compound has the formula (I): (I); Or its pharmaceutically acceptable salt.
3. The compound of claim 1, wherein Ar1 is And T does not exist.
4. The compound of claim 1, wherein the compound has the formula (IIIB), (IIIB-a), or (IIIB-b): (IIIB)、 (IIIB-a) or (IIIB-b); Or its pharmaceutically acceptable salt, wherein: n1 is an integer in the range of 0 to 4; and n2 is an integer in the range of 0 to 4.
5. The compound of claim 1, wherein the compound is selected from the compounds described in Table B2 and their pharmaceutically acceptable salts.
6. A pharmaceutical composition comprising a compound according to any one of claims 1-5 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
7. Use of the compound according to any one of claims 1-5 in the preparation of a medicament for regulating orexin-2 receptor activity; optionally, the activity is in vitro or in vivo.
8. Use of the compound of any one of claims 1-5 in the preparation of a medicament for the treatment or prevention of diseases or disorders related to the orexin-2 receptor.
9. The use according to claim 8, wherein the disease or disorder is narcolepsy, excessive sleep disorder, neurodegenerative disorder, neurological disorder, symptoms of rare genetic disorder, mental disorder, psychological disorder, circadian rhythm disorder, metabolic syndrome, osteoporosis, heart failure, coma, or promoting anesthesia recovery.
10. The use according to claim 8, wherein the disease or disorder is narcolepsy, idiopathic hypersomnia, sleep apnea, or insomnia.
Citation Information
Patent Citations
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4522811A
Method and apparatus for producing position addressable combinatorial libraries
US5763263A
Heterocyclic compound and use thereof
WO2019027058A1
Heterocyclic compound and use thereof
WO2020158958A1
